# Long-Term Effect of Surface Roughness and Patients' Factors on Crestal Bone Loss at Dental Implants. A Systematic Review and Meta-Analysis

Ron Doornewaard, DDS;\* Véronique Christiaens, DDS, MSc;<sup>†</sup> Hugo De Bruyn, MSc, PhD;<sup>‡</sup> Magnus Jacobsson, MD, PhD;<sup>§</sup> Jan Cosyn, DDS, MSc, PhD;<sup>\*</sup> Stijn Vervaeke, DDS, MSc, PhD;\*\* Wolfgang Jacquet, MSc, PhD<sup>††</sup>

#### **ABSTRACT**

Publications from 2011 to 2015 were selected to evaluate effect of implant surface roughness on long-term bone loss as surrogate for peri-implantitis risk. 87 out of 2,566 papers reported the mean bone loss after at least 5 years of function. Estimation of the proportion of implants with bone loss above 1, 2, and 3 mm as well as analysis the effect of implant surface roughness, smoking, and history of periodontitis was performed. By means of the provided statistical information of bone loss (mean and standard deviation) the prevalence of implants with bone loss ranging from 1 to 3 mm was estimated. The bone loss was used as a surrogate parameter for "peri-implantitis" given the fact that "periimplantitis" prevalence was not reported in most studies or when reported, the diagnostic criteria were unclear or of dubious quality. The outcome of this review suggests that peri-implant bone loss around minimally rough implant systems was statistically significant less in comparison to the moderately rough and rough implant systems. No statistically significant difference was observed between moderately rough and rough implant systems. The studies that compared implants with comparable design and different surface roughness, showed less average peri-implant bone loss around the less rough surfaces in the meta-analysis. However, due to the heterogeneity of the papers and the multifactorial cause for bone loss, the impact of surface roughness alone seems rather limited and of minimal clinical importance. Irrespective of surface topography or implant brand, the average weighted implant survival rate was 97.3% after 5 years or more of loading. If considering 3 mm bone loss after at least 5 years to represent the presence of "periimplantitis," less than 5% of the implants were affected. The meta-analysis indicated that periodontal history and smoking habits yielded more bone loss.

KEY WORDS: bone loss, dental implant, implant survival, meta-analysis, peri-implantitis, surface roughness, surface topography, systematic review

\*Specialist in training, Master student Periodontology, Department Periodontology & Oral Implantology, Dental School, Faculty Medicine and Health Sciences, Ghent University Belgium; †PhD student, Department Periodontology & Oral Implantology, Dental School, Faculty Medicine and Health Sciences, Ghent University Belgium; †full professor and chairman, Department Periodontology & Oral Implantology, Dental School, Faculty Medicine and Health Sciences, Ghent University Belgium, visiting professor, Department of Prosthodontics, Malmö University, Sweden; \*professor, Department Periodontology & Oral Implantology, Dental School, Faculty Medicine and Health Sciences, Ghent University Belgium, professor, Faculty of Medicine and Health Sciences, Oral Health Research Group ORHE, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; ††professor, Faculty of Medicine and Pharmacy, Department of Educational Sciences EDWE-LOCI, Faculty of Psychology and Educational Sciences, Vrije Universiteit Brussel, Brussels, Belgium, professor, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium, professor, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium, professor, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium

Reprint requests: Dr. Hugo De Bruyn, Department Periodontology & Oral Implantology, Dental School, Faculty Medicine and Health Sciences, Ghent University Belgium, De Pintelaan 185 P8, B-9000 Ghent, Belgium; e-mail: hugo.debruyn@ugent.be

© 2016 Wiley Periodicals, Inc.

DOI 10.1111/cid.12457

#### INTRODUCTION

Today, achievement of osseointegration is no longer the only key issue in research related to oral implantology as the predictability of implant therapy is high due to improvements of biomaterials and clinical procedures. Multiple long-term studies show successful treatment outcomes in terms of functional rehabilitations with survival rates ranging from 89.5 to 99.2%. <sup>1–6</sup> Instead, the focus has shifted to peri-implant bone stability, which is paramount for long-term success. Bone loss may lead to complications such as soft tissue recession, "peri-implantitis," implant fractures, and eventually loss of the implant.

Although dental implants have demonstrated favorable long-term results,<sup>7–12</sup> failures do occur and can be related to different factors. For instance, early implant failures have been related to excessive surgical trauma, an impaired healing ability, premature loading, and infection. In addition, late failures are mostly attributed to occlusal overload and/or progressive peri-implant bone loss.<sup>13</sup> Most patients of today have lost one or a few teeth and have high demands on the esthetic outcome. Peri-implant bone stability is a prerequisite for soft tissue preservation and hence, bone loss may lead to soft tissue recession and a poor esthetic outcome. <sup>14,15</sup>

Likewise periodontitis, peri-implantitis is a multifactorial disease but associated with pathogens colonizing the subgingival biofilm, and the host response.<sup>16</sup> Peri-implant mucositis has been described as a reversible inflammation of the peri-implant softtissues without signs of loss of the supporting bone. Peri-implantitis is defined as inflammation of the soft tissues in combination with ongoing loss of the supporting peri-implant bone beyond the physiological bone adaptation. 17 The reasons for the inflammation is multifactorial and under debate and especially diagnostic thresholds or diagnostic methods in general, are currently leading to biased reports on periimplantitis prevalences. Some authors look on "periimplantitis" as a biofilm induced disease while others regard this as an imbalanced foreign body response. However, not every single implant presenting periimplant bone loss can be defined as peri-implantitis. It is well documented that the initial bone loss is an inevitable reaction to surgery and loading and known clinically as the establishment of a soft tissue seal called "biologic width." 18-20

Poor oral hygiene is known as an important risk factor in the development and progression of periodontal disease. Poor oral hygiene initiates a persistent gingivitis, which results in a 46-times higher risk for tooth loss. Similarly, there is evidence that good oral hygiene should be recommended to prevent bleeding and pocket formation around implants. Patient less compliant with maintenance are also more prone to implant failure.

Different systematic reviews have shown that patients with existing or ongoing periodontitis are more likely to experience implant failure and biological complications. This could be related to the type of microbiotia in these patients and the ability of forming biofilms. It could also reflect a stronger immunological response to foreign bodies such as biofilm, plaque, and implant components. However, it is difficult to draw strong conclusions due to the high heterogeneity among the studies and methodological variability.<sup>33</sup>

Tobacco smoke contains nearly 4,000 chemicals such as carbon monoxide, hydrogen cyanide, reactive oxidizing radicals. Some of those chemicals are known to be toxic and as a consequence smoking harms nearly every organ in the body including the tissues within the oral cavity. The negative effect of smoking is attributed to the impaired vascularity of the periodontal tissues rather than a vasoconstrictive effect.<sup>34</sup> By affecting the revascularization it may lead to an impaired healing after surgery. Different systematic review identified smoking as a factor affecting implant survival and peri-implant bone loss.<sup>27,35,36</sup> Additionally, Lindquist and colleagues identified smoking the predominant factor affecting periimplant bone loss. However, good oral hygiene reduced the pernicioous effects of smoking while poor oral hygiene aggravated bone resorption.<sup>37</sup>

Besides, the above-mentioned patient-related factors, implant-related factors can possibly influence implant treatment outcome. Today, most marketed implant surfaces are moderately rough with  $S_a$  values between 1.1 and 2  $\mu$ m. A brief overview of various surface roughness for some implant brands is given in Table 1. Increasing implant surface roughness, induces qualitative and quantitative changes in biofilm formation. Quirynen and colleagues suggested that implants with increased surface roughness may be more prone to peri-implant bone loss

TABLE 1 Surface Roughne	ss and Corresponding Sa Valu	ies (μm) and Some Implant Brands
Surface roughness	Sa value	Some implant brands
Smooth	$< 0.5~\mu\mathrm{m}$	Experimental not clinically available
Minimally rough	$0.5-1~\mu\mathrm{m}$	Machined Brånemark implants, Osseotite, Nanotite
Moderately rough	$>$ 1–2 $\mu m$	SLA, TiUnite, Osseospeed, TiOblast, Southern
Rough	> 2 μm	IMZ, TPS, Ankylos, Friadent, Xive

and consequently, late implant failure.<sup>28</sup> Conversely, Chappuis and colleagues showed that even rough TPS-coated implants can be very successful presenting very limited peri-implant bone loss after 20 years follow-up in a well-maintained population.<sup>39</sup> One can conclude that the literature is inconclusive about the effect of implant surface roughness on implant success.

Hence the aim of this study was to scrutinize whether long-term peri-implant bone loss, beyond physiologic bone adaptation, is affected by implant surface roughness and/or patient-related factors such as smoking and history of periodontitis.

#### **MATERIALS AND METHODS**

## Paper Selection

Since it was the aim of the paper to assess long-term bone loss as surrogate variable for peri-implantitis and to scrutinize the type of studies and the level of quality of reporting, it was decided to conduct a broad literature search using the Pubmed database of the US National Library of Medicine for articles. Publications from 2011 up to December 24, 2015 were the general selected using search (((((("bone loss") OR "peri-implantitis")) OR "peri implant")) AND dental implant). It was opted not to perform a strict review using the terminology "Peri-Implantitis" [Mesh] as search criterion due to the limitation of the generated output to only 426 papers. Because most surface-modified implants were launched commercially at the time of the millennium change, the time frame was set to 2011 to 2015 because this increased the probability to select predominantly currently commercially available implant brands and various rather new surfaces. Furthermore, it seemed logical to have a literature search cut-off at 2011 because peri-implantitis is reported after longer follow-up times and the scientific community has taken special interest in clinical research on periimplantitis after consensus meetings with specific guidelines for research from 2006 onwards.  $^{40-43}$ 

The list of generated articles was obtained through elimination based on the title and detailed information given in the abstract. Further evaluation and refining of the selected papers was performed by reading the papers and registering the described results in the data set. In case of disagreement over the inclusion/exclusion, both evaluators (RD & VC) discussed and reached a consensus or, in case of further doubt, a third evaluator was consulted (HDB).

To be included in the study, the papers had to be published in English, report on bone loss compared to a baseline measurement and include at least 10 patients after a minimal mean follow-up time of 5 years. Only studies discussing straightforward implant treatment in systemically healthy patients, as the test strategies were included. Hence, studies describing implant treatments in tumor-resected areas, studies involving extensive bone grafts or zygomatic implants were excluded. Exceptional, experimental or uncommon implant designs, as well as implants with unknown surface topography, were excluded. Studies were additionally rejected when statistical evaluation was hampered because of incomplete data reporting, such as lacking failure rate, implant or patient numbers, bone loss and standard deviation calculated on implant level. However, studies lacking standard deviation on bone loss were included for calculating implant survival.

Table 2 gives an overview of exclusion criteria and the references of the excluded papers. The review did not exclude studies with smokers, patients with periodontal history, controlled diabetes, or implants in sinus lifted bone. These procedures are today considered part of daily good clinical practice. To avoid a biased selection and to ensure that the papers reflected the daily clinical situation, no distinction was made based on study design (prospective or

TABLE 2 Excluded Papers and Exclusion Ro	eason
Follow-up <5 years	
Kan and colleagues <sup>44</sup>	2011
Lopez-Piriz <sup>45</sup>	2012
Soardi and colleagues <sup>46</sup>	2012
Paul and colleagues <sup>47</sup>	2013
Dagorne and colleagues <sup>48</sup>	2014
Ata-Ali and colleagues <sup>49</sup>	2015
Jervoe-Storm and colleagues <sup>50</sup>	2015
<10 patients per treatment group at baseline	
Zafiropoulos and colleagues <sup>51</sup>	2013
Romanos and colleagues <sup>52</sup>	2013
<10 patients per treatment group after at least	5 years
Vanlioglu and colleagues <sup>53</sup>	2012
Bahat and colleagues <sup>54</sup>	2012
Romeo and colleagues <sup>55</sup>	2014
Incomplete data about bone loss after at least 5	years
Cortellini and colleagues <sup>56</sup>	2011
Ozkan and colleagues <sup>57</sup>	2011
Ozkan and colleagues <sup>58</sup>	2011
Akoglu and colleagues <sup>59</sup>	2011
Stacchi and colleagues <sup>60</sup>	2012
Maló and colleagues <sup>61</sup>	2012
Fugazzotto <sup>62</sup>	2012
Swierkot and colleagues <sup>63</sup>	2012
Degidi and colleagues <sup>64</sup>	2012
Ormianer and colleagues <sup>65</sup>	2012
Rocci and colleagues <sup>66</sup>	2012
Covani and colleagues <sup>67</sup>	2012
Wilson and colleagues <sup>68</sup>	2013
Harel and colleagues <sup>69</sup>	2013
Romanos and colleagues <sup>70</sup>	2013
Harel and colleagues <sup>71</sup>	2013
Canullo and colleagues <sup>72</sup>	2016
Felice and colleagues <sup>73</sup>	2014
Frisch and colleagues <sup>74</sup>	2014
Woelber and colleagues <sup>75</sup>	2016
Maló and colleagues <sup>76</sup>	2015
Trullenque-Eriksson and colleagues <sup>77</sup>	2015
Jemt and colleagues <sup>78</sup>	2015
Melo and colleagues <sup>79</sup>	2015
Incomplete data about number of patients and	or
implants	
Yaltirik and colleagues <sup>80</sup>	2011
Ueda and colleagues <sup>81</sup>	2011
Stoker and colleagues <sup>82</sup>	2012
Krennmair and colleagues <sup>83</sup>	2011
Oliva and colleagues <sup>84</sup>	2012
Moeintaghavi and colleagues <sup>85</sup>	2012

Table 2. cont.	
Follow-up <5 years	
Pettersson and colleagues <sup>86</sup>	2015
Sivolella and colleagues <sup>87</sup>	2013
Berberi and colleagues <sup>88</sup>	2014
Mangano and colleagues <sup>89</sup>	2014
Rossi and colleagues <sup>90</sup>	2015
Vázquez Alvarez and colleagues <sup>91</sup>	2014
Nack and colleagues <sup>92</sup>	2015
Korfage and colleagues <sup>93</sup>	2014
Cavalli and colleagues <sup>94</sup>	2015
Maló and colleagues <sup>95</sup>	2014
Anitua and colleagues <sup>96</sup>	2016
Ebinger and colleagues <sup>97</sup>	2016
Jeong and colleagues <sup>98</sup>	2015
Konstantinidis and colleagues <sup>99</sup>	2015
Fretwurst and colleagues <sup>100</sup>	2015
Krebs and colleagues <sup>101</sup>	2015
Quaranta and colleagues <sup>102</sup>	2015
Rossi and colleagues <sup>103</sup>	2016
Incomplete data about follow-up time	
Mijiritsky and colleagues <sup>104</sup>	2013
Zirconia implants	
Grassi and colleagues <sup>105</sup>	2015
Autologous onlay grafted bone	
Dasmah and colleagues <sup>106</sup>	2013
De Bruyn and colleagues <sup>107</sup>	2013
Sbordone and colleagues <sup>108</sup>	2012
Stellingsma and colleagues <sup>109</sup>	2014
Duttenhoefer and colleagues <sup>110</sup>	2015
Patients treated with implants after oral tumors	
Zou and colleagues <sup>111</sup>	2015
No consensus about bone loss	
Hjalmarsson and colleagues <sup>112</sup>	2011

retrospective) or surgical or prosthetic treatment protocol.

# Statistical Analysis

For each study the mean bone loss was used together with the number of implants to calculate the weight of the study in the overall statistical analysis of bone loss and to estimate the proportion of implants with bone loss above 1, 2, and 3 mm. Analysis was performed additionally per implant surface roughness group and qualified as minimally rough, moderately rough, rough, or mixed/unknown. The latter included studies with unspecified implant surface roughness or

where data were presented without making distinction between implant brands or surface topography.

For the descriptive statistics the results of the individual studies were weighted by the number of implants to prevent studies with extremely homogenous groups dominating the results. After the descriptive followed the assessment of the inter study variability. Preliminary analysis performed showed that the multitude of intervening factors jeopardized the successful reduction of the intra study variability by means of a meta-regression. As argument to sustain this statement the heterogeneity estimates of the random effects model were included and the results of meta-regression models predicting mean bone loss through mediating factors, such as smoking and roughness were presented. The aim of meta-analysis is the recombination of results of several studies through increased power and to detect influences that otherwise would appear to be statistically insignificant. Extreme heterogeneity of the studies does not allow for the straightforward application of metaanalytic statistics and testing strategies. Therefore, a subgroup analysis was conducted for roughness, smoking, and periodontal history based on studies that allowed for "paired" comparisons. Nullhypotheses were the equality of bone loss between minimally rough and moderately rough implant surfaces, smokers and non-smokers, and healthy patients and patients with a periodontal history, respectively. Throughout the meta-analytic analysis the study results are weighted by the inverse of the variance of the effect sizes. Heterogeneity was considered to be high if I<sup>2</sup> exceeded 70%, between 50% and 70% the heterogeneity was considered to be medium, and below 50% small. When the heterogeneity was revealed to be statistically significant (p < .05) the random effects model was interpreted. If not significant, the fixed model was evaluated.

Descriptive statistics and the recombination of results were performed using MatLab R2015b version (8.6.0.267246) (The MathWorks, Inc., Natick, MA, USA). The meta-regression and fixed and random effects modeling were performed using the statistical package R version 3.1.0 (2014-04-10) (The R foundation for Statistical Computing), platform: x86\_64-w64-mingw32/x64 (64-bit) with "metaphor" package (version 1.9-7) for meta-regressions and the package "meta" version 4.3-2 for random and fixed effect modeling.

#### **RESULTS**

## Selection of Papers

The literature search yielded 6,445 studies starting in 1972 up to 2015. Of the last 2,566 publications between 2011 and August 14, 2015, in total 156 were deemed appropriate and selected by the two examiners taking the initial selection criteria into account. A further selection after reading of the paper disqualified another 69 papers for several reasons, among others the lack of standard deviation on bone loss. This was an essential factor to allow statistical estimation of the proportion of implants with an arbitrarily selected threshold for bone loss (Table 2).

# Quality of the Papers

The paper search revealed in total 87 included studies (summarized in Table 3) that reported a mean bone loss on implant level over a 5 to 20 year follow-up time; 48 were prospective and 39 were retrospective. Some papers compared different treatment protocols which were considered as separate study groups for the statistical analysis of implant survival or bone loss calculation because some pertained to different surface or implant types as well as different treatment protocols. In the 123 treatment groups in total 15,695 implants were inserted in 6,755 patients and information about mean bone loss at the last examination visit was available from 13,970 implants after at least 5 years of implant function. The total drop-out of implants from baseline to the evaluation time point was 11% for the 87 selected papers.

Fifty-three out of 87 studies pertained to 10,533 originally placed implants from the portfolio of the three world leading companies Dentsply, Nobel Biocare and Straumann representing proportionally 67.1% from the total material. With 9,136/10,533 initially placed implants remaining at follow-up, the dropout rate was 13.3%.

Information on probing depth and bleeding on probing was available in only 40 and 49 of the included studies, respectively. Twenty-seven out of 87 papers reported peri-implantitis prevalence on implant level (Table 4) ranging between 0% and 39.7%. This large range can be explained by the arbitrarily chosen thresholds and diagnostic parameters for disease. The cut-off bone loss for peri-implantitis ranged from 1 to 3 mm and the cut-off probing

TABLE 3 O Implants at (1= unknow	Vervie t Basel wn or	iw of Find line, Impl mixture	TABLE 3 Overview of Finally Included Papers with Implants at Baseline, Implants at Follow-Up, Mean (1= unknown or mixture of surfaces, 2= smooth, 3	l Papers w w-Up, Me 2= smoot	rith Study an Impla h, 3= mo	n Study Design (P = prospe   Implant Bone Loss (mm)	(P = pro Loss (m rough,	spective; R m) and Sta 4= rough)	R = retrospect Indard Devia	n Study Design (P = prospective; R = retrospective), Mean Follow-Up (years), Number of Patients and Implant Bone Loss (mm) and Standard Deviation, Implant Survival Rate (%) and Surface Roughness 3 = moderately rough, 4 = rough)	ollow-Up (y Survival Ra	ears), Numboate (%) and S	er of Patiel Surface Rou	nts and ughness
		Study	Treatment	Mean follow-up		Patients Implants Implants at at at	nplants at	lmplant		Baseline	Mean implant bone	Standard deviation bone	Implant	Surface
Author	Year	design	subgroups	years	baseline k	baseline baseline follow-up	dn-wolle	brand	Surface	time	loss (mm)	loss (mm)	rate %	roughness
Becker and	2016	Ф		6.5	31	84	40	Nobel Biocare	Mixed	1	-0.10		94.60%	Mixed
Imburgia & Del Fabbro <sup>114</sup>	2015	×		8.8	41	205	205	Nobel Biocare	TiUnite	0	0.43	1.15	96.10%	ю
Hoeksema and colleagues <sup>115</sup>	2016	Ф	1: Older patients	10		106	64	Straumann	TPS	1	1.20	1.20	93.40%	4
0			2: Young patients	10	105	104		Straumann	TPS	1	1.20	1.10	97.10%	4
Vandeweghe and colleagues <sup>116</sup>	2016a	ĸ		7.5	46	2111	211 8	Southern	Mod rough	0	1.17	0.49	99.50%	6
	2016b	æ	1: Moderately	14.3		121	121 8	Southern	Mod rough	0	1.73	1.54	97.00%	ю
coneagnes			rougn 2: Smooth	14.3	33	9/2	3 92	Southern	Machined	0	1.41	0.92		2
Nedir and	2016	Ь		10	17	25		Straumann	SLA	0	1.00	0.90	100.00%	e,
colleagues <sup>118</sup>		ţ		Ş	i			:		¢	ć	i c	100	ć
Fark and colleagues <sup>119</sup>	5107	¥		10	4/	747	747	Implantium Dental Implant	Moderately	o	0.28	0.78	97.90%	n
Eerdekens and	2015	Ь		ĸ	10	09	10	Ankylos	Ā	1	09.0	1.12	%02.96	4
colleagues <sup>120</sup>			,					;						
Perrotti and colleagues <sup>121</sup>	2015	പ	1: Tuberplant	10	97	29	) (9	Oralplant	TPSS		1.31	0.74	98.60%	4
)			2: Bioplant	10		59		Oralplant	TPSS	1	0.74	0.92	100.00%	4
Romanos and	2016	Ь	1: Immediate	10.1	12	30	30	Ankylos	Ankylos	6	0.57	1.06	100.00%	4
colleagues <sup>122</sup>			loading 2: Delayed loading	10.4		30	30	Ankylos	Ankylos	6	1.12	1.30	100.00%	4
Zhao and	2016	Ж			45	45		Straumann	SLA	1	1.10	0.92	100.00%	8
colleagues <sup>123</sup>	2014	£		G	ç	701		N. Marie	our.	c	ç		90	,
Crespi and colleagues <sup>124</sup>	7014	<u>.</u>	I: Screw retained	ø	97	961	961	Cuttink	IFS	Þ	0.42		98.30%	4
			2: Cement retained	8		136	136 (	Outlink	TPS	0	0.67		100.00%	4
van Velzen and	2015	Ь		10	250	909	367	Straumann	SLA	0	1.21	0.94	99.70%	3
colleagues Trullendue-Eriksson	2014	×		13.19	105	342	342 I	Mixed	Mixed	1	1.84	1.35	%09:06	Mixed
& Guisado-														
Moya Joda and	2015	×		ſV	86	316	316	Ankylos	Ankylos	1	1.02	1.25	97.20%	4
colleagues <sup>127</sup>														
Meijer and colleagues <sup>128</sup>	2014	Q.		10	150	240	240	Mixed	Mixed	1	1.10	1.10	95.30%	Mixed

Author 1	Table 3. cont.	ont.													
Study   Treatment   Collow-Lot   Act   Act   Act   Implant   Surface   Sur					Mon	Datiente	molante	molante			Racelina	Mean	Standard	tue um	
Viet         design         Librational States         State and			Study	Treatment	follow-up	at	at	at	Implant		radiograph	bone	bone	survival	Surface
1314   P   12   13   13   13   13   13   13   13	Author	Year	design	subgroups	years	baseline l	baseline 1	dn-wollo.	brand	Surface	time	loss (mm)	loss (mm)	rate %	roughness
2014   Particle   Pa	Slotte and	2015	Ь		5	32	98		Straumann	SLA	1	0.53	0.34	92.20%	ε
2014   P. E. Parial case   S. 10   15   15   15   15   15   15   15	colleagues <sup>129</sup>														
2014   P   1 Parial case   5   20   15   1 Parial case   5   1 P	Schropp and	2014	Ъ		10	72	63		Biomet/3I	Osseotite	0	0.67	0.98	unknown	2
2014   P.   2. Full class   S	colleagues	7100	£		ı	ć	L			MC 1	c	-	c c	00 400/	c
2014a   Paris   S. Pell case   S. 19   23   15   15   15   15   15   15   15   1	colleagues <sup>131</sup>	7014	Σ,	I: Faruai cases	n	70	66		Inommen	Moderately	Þ	01:10	0.00	98.40%	n
2016   P   2018   S   24   25   25   25   25   25   25   25	Sangana			2: Full cases	ιΩ		23		Chommen	Moderately	0	1.50	0.90		e
2014   P   P   P   P   P   P   P   P   P							i			rough					•
2015   R	Cooper and	2014a	Ь		ß	19	23		Astra Tech	Osseospeed	0	0.18	0.79	96.50%	ю
2015   R	colleagues <sup>132</sup>														
2015   R	Vervaeke and	2016	Ь		6	20	320		Astra Tech	TiOblast	0	1.68	2.08	99.20%	ε
2015   R	colleagues														
2014   Particular   Lanceding   Lancedin	Mangano and colleagues <sup>134</sup>	2015	ĸ		20	49	178		Mac System	Unknown	-	1.80	0.60	97.20%	Unknown
2014   Particular   6.2   4.9   16.3   15.9   Unknown   Rough   Roug	Simion and	2015	М		12	29	59		Nobel Biocare	Machined	1	1.34	0.79	93.20%	2
10   1   1   1   1   1   1   1   1   1	colleagues <sup>135</sup>														
Moding   Particular   Particu	Tealdo and	2014	Ь	1: Immediate	6.2	49	163		Unknown	Rough	0	1.12	1.12	93.90%	4
2014 P I: Immediate 6.2 47 47 45 Khono Implants Unknown Rough 0 134 144 95.90% 95.70% 10 10 10 10 10 10 10 10 10 10 10 10 10	colleagues <sup>136</sup>			loading											
2014 P 1: Immediate 5 113 55 55 Aktn Tech Ossospeed 0 0.43 0.63 95.00% 95.00% 1.00 placement 2 Delayed 5 113 55 55 Aktn Tech Ossospeed 0 0.43 0.63 95.00% 95.00% 1.00 placement 2 Delayed 5 113 55 55 Aktn Tech Ossospeed 0 0.43 0.63 95.00% 1.00 placement 2 Delayed 5 113 55 55 Aktn Tech Ossospeed 0 0.43 0.63 95.00% 1.00 placement 1 10 2 0.04 41 102 0.02 102 Calcitek 0 0.128 0.038 0.62 95.00% 1.00 placement 1 10 2 0 54 54 Frialit Friadent 1 0.60 0.26 95.00% 1.00 placement 1 10.3 75 111 87 BTT Unknown 0 0.95 0.65 95.00% 1.00 placement 1 10.00 placement				2: Delayed loading			26		Unknown	Rough	0	1.94	1.44	95.90%	4
2014   P   1. Immediate   5   113   55   Asta Tech   Oseospeed   0   043   063   95.00%     2204   R   Asta Tech   Diacement   7.7   41   102   Calcitek   Calcitek   Calcitek   Calcitek   0.038   0.038   0.045   95.00%     2014   R   Asta Tech   R   Asta Tech   Railit   Findent   Railit	Covani and colleagues <sup>137</sup>	2014	Δ <sub>1</sub>		Ŋ	47	47		Khono Implants	Unknown	0	1.08	0.43	95.70%	Unknown
2014   R   1-periodontally   10   120   20   1	Cooper and	2014h	Д	1. Immediate	ư	113	55		Astra Tech	Deansoaso	C	0.43	0.63	95 00%	cr
2. Delayed 5 58 Astra Tech Osecopeed 0 0.38 0.62 98.00% 98.00% placement 7.7 41 102 Calcitek Calcitek 0.21 0.0 1.28 1.06 99.00% 99.00% 1.2 1.0 1.0 20 54 Frialit Friadent 1 0.0 0.0 1.28 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	colleagues <sup>138</sup>	22.702	•	placement	,		3		noar month	na decree	>				'n
2014   R   Pacement   2.7				2: Delayed	5		28		Astra Tech	Osseospeed	0	0.38	0.62	98.00%	3
2014 R R 1.2 P 10 20 S4 Frialit Friadent 0 1.28 1.06 99.00% 99.00				placement											
2014 R R 1: Periodontally 10 120 20 54 Frialit Friadent 1 0.60 0.26 96.30% 1.00.00% 1.58 1.61 100.00% 1.00.00% 1.58 1.61 100.00% 1.00.00% 1.58 1.61 100.00% 1.00.00% 1.00 1.00 1.00 1.00 1	Leventi and	2014	М		7.7	41	102		Calcitek	Calcitek	0	1.28	1.06	%00'66	4
2014 R 882 73 167 160 Nobel Biocare TiUnite 0 1.58 1.61 100.00% 96.30% 96.30% 1.10 R 1.5 Periodontally 10 120 20 20 Nobel Biocare Machined 1 2.32 0.41 95.00% 95.00% 1.00 Nobel Biocare Adelined 1 3.47 1.09 90.00% 90.00% snoking 10 10 10 Nobel Biocare Rachined 1 3.47 1.09 90.00%	colleagues														
2014 R 1: Periodontally 10 120 20 20 Nobel Biocare TiUnite 0 1.58 1.61 100.00% 1.60 Nobel Biocare TiUnite 0 1.58 1.61 100.00% 1.60 10.00% 1.61 100.0	Meyle and	2014	Д		10	20	54		Frialit	Friadent	1	09.0	0.26	96.30%	4
2014 R 1: Periodontally 10 120 20 20 Nobel Biocare TiUnite 0 1:58 1.61 100.00% compromised non-smoking 10 10 10 Nobel Biocare Machined 1 3.47 1.09 90.00% snoking sanoking san	colleagues														
2014 R 1: Periodontally 10 120 20 20 Nobel Biocare Machined 1 3.47 1.09 90.00% 98.90% 20.00 Nobel Biocare Machined 1 3.47 1.09 90.00% 90.00% snoking 10 10 Nobel Biocare Machined 1 3.47 1.09 90.00% 1	Pozzi and	2014	×		8.82	73	167		Nobel Biocare	TiUnite	0	1.58	1.61	100.00%	ю
2014 R 1: Periodontally 10 120 20 20 Nobel Biocare Machined 1 2.32 0.41 95.00% compromised non smoking compromised smoking stock of the compromised smoking compromised smoking compromised smoking compromised smoking compromised smoking sm	colleagues <sup>141</sup>														
2014 R I: Periodontally 10 120 20 20 Nobel Biocare Machined 1 2.32 0.41 95.00% compromised no snoking 10 10 Nobel Biocare Machined 1 3.47 1.09 90.00% snoking snoking 10 10 Nobel Biocare Machined 1 3.47 1.09 90.00%	Anitua and	2014	×		10.3	75	Ξ		BTI	Unknown	0	0.95	0.65	98.90%	Unknown
2. Periodontally 10 10 Nobel Biocare Machined 1 3.47 1.09 90.00% snoking snoking	Rasperini and	2014	2	1. Periodontally	01	120	30		Nobel Biocare	Machined	-	232	0.41	95 00%	c
compromised non smoking 10 10 Nobel Biocare Machined 1 3.47 1.09 90.00% compromised snoking	Maspellin and	1107	4	1. 1 CHOCORdany	27	071	04		Nobel Diocale	Machined	•	4	14:0	0/00:57	4
10 10 Nobel Biocare Machined 1 3.47 1.09 90.00%	colleagues			compromised											
10 10 100cate Machined 1 5.47 1.09 900070				non smoking	01		9		Johol Biogen	Machine	-	6 7	001	700000	c
smoking				2. renountany	2		10		Nobel Diocale	Macmica	,	7:-7	70.1	0.000	4
				complaina											

Table 3. cont.	ont.													
				Mean	Mean Patients Implants Implants	nplants Ir	nplants			Baseline	Mean implant	Standard deviation	Implant	
		Study	Treatment	follow-up at	at	at	at	Implant		radiograph	pone	pone	survival	Surface
Author	Year	design	subgroups	years	baseline baseline follow-up	aseline fo	llow-up	brand	Surface	time	loss (mm)	loss (mm)	rate %	roughness
			3: Periodontally	10		20	20 S	Straumann	TPS	1	2.32	0.41	85.00%	4
			compromised											
			non smoking											
			4: Periodontally	10		10	10 S	Straumann	TPS	1	3.77	1.43	80.00%	4
			compromised											
			smoking											
			5: Periodontally	10		20	20 N	Nobel Biocare	Machined	1	1.43	0.38	92.00%	2
			healthy non											
			smoking	ţ					;	,	,	:	9	,
			6: Periodontally	10		10	10	Nobel Biocare	Machined	Т	2.65	0.41	%00.06	7
			molina											
			SHOKING	9		S			out		i.	ć.	900	•
			/: Periodontally	10		07	S 07	Straumann	11/5	-	1.95	0.42	95.00%	4
			healthy non											
			smoking	,		4			0.00	,	į		4	
			8: Periodontally	10		10	10 s	Straumann	TPS	-	2.51	0.31	100.00%	4
			healthy											
	100	F	smoking	;	G	000				c	c c		000	c
Mozzati and	5107	¥		=	06	409	168 N	Nobel blocare	LIUnite	O	0.60	111	97.10%	o
colleagues	2013	Е	1. Telegoonis	0	-	-			Sult	o	330	Q Q	900 001	4
Zou and	5107	¥	i: rerescopic	o	44	711	100	Straumann	1173	7	1.30	0.40	100.00%	4
colleagues			overdenture 2. Bar overdenture			105	20	Strain ann	SdL	o	1 20	090	100 00%	4
			z. Dar överdenture	0		COL		Hamilailli -	ira	6	1.20	0.00	100.00%	<b>1</b> *
Donati and	2015	Д		ιn	151	161	140 A	Astra Tech	Osseospeed	0	0.32	1.15	95.60%	m
colleagues														
Rocci and	2013	Д	1: TiUnite	6	44	99	51 N	Nobel Biocare	TiUnite	0	1.40		95.50%	m
colleagues						ł			:	¢	i i		i	ć
		-	z: Machined	χ.		6		Nobel blocare	Machined	0	1.70		85.50%	7
Dhima and	2013	×		6	81	81	81 N	Nobel Biocare	TiUnite	0	-0.94	0.99	100.00%	7
coneagues	5100	E		u	ć	15.0			-	c		98	2000 001	c
Nrennmair and	2107	¥		c:c	747	761	761	Camlog	Camiog	0	1.21	0.36	100.00%	o
Akca and	2013	22	1. Ball abutment	ıc	29	88	86	Straumann	A IS	σ	0.77	0.31	%00 26	æ
colleagnee <sup>150</sup>		4	overdenture	,	ì	2								,
canganana			2. Locator abut-	ư		00	3 00	Straumann	SI A	σ	05.0	0.13	100 00%	'n
			2. LOCATOI ADUL-	n		04		Hammanni	SLA	6	60:0	0.10	100:0020	ò
			ment											
460	2013	Q	o con de la contra con la contra con la contra cont	7	7.7	107	701	Mohol Biogen	Tillmite	c	1 40	1 03	100 000%	c
Gelb and	5107	¥		cc./	/6	10/		tobel blocare	Homite	0	1.49	1.03	100.00%	o
concagues														

Table 3. cont.	nt.													
				Mean	Patients I	Mean Patients Implants Implants	mplants			Baseline	Mean	Standard deviation	Implant	
		Study	Treatment	follow-up	at	at	at	Implant		radiograph	hone	bone	survival	Surface
Author	Year	design	subgroups	years	baseline	baseline baseline follow-up	dn-wollo	brand	Surface	time	loss (mm)	loss (mm)	rate %	roughness
Schwarz and	2014	Ь		7.2	37	185	126 I	Frialoc system	Frialit	0	1.10	1.20	89.20%	4
colleagues <sup>152</sup>														
Wagenberg and	2013	×		10.18	541	1,187	1,181	Nobel Biocare	Machined	0	0.52	0.79	99.62%	2
colleagues 153														
Chappuis and	2013	×		20	29	92	82	Straumann	TPS	0	0.14	1.09	89.50%	4
Savardoust and	2013	×	1: Smokers.	ιc	80	26	56	Nobel Biocare	TiUnite	-	1.16	1.80	92.90%	m
colleagues <sup>154</sup>			TiUnite		}	1								•
			2: Never smokers,	S		52	52	Nobel Biocare	TiUnite	1	1.26	1.08		3
			TiUnite											
			3: Smokers,	Ŋ		78	78 1	Nobel Biocare	Machined	1	1.54	1.85		2
			Machined						:					
			4: Never smokers, Machined	Ŋ		99	99	Nobel Biocare	Machined	_	0.84	1.14		7
Calvo-Guirado	2014	Ь		10	64	98	86 I	Biomet/3I	Osseotite	0	1.01	0.22	97.10%	2
and														
colleagues	2013	ρ	1. Then	4	o tr	17	7.	Actua Tach	TiOblast	-	O U	030	900 001	ч
colleames <sup>156</sup>	6102	4	abutment	o	Ç.	Ť		Asua lecii	LIODIASI	1	0.50	00:00	100.00%	n
conganno			2: Zirconium	9		82	38	Astra Tech	TiOblast	_	0.40	0.20	100 00%	ĸ
			abutment			2				•				ì
Dam and	2014	Ь		5.5	174	378	378	Straumann	Mixed	0	1.12	1.10	Unknown	Mixed
colleagues <sup>157</sup>														
Buser and	2013	Д		7	41	41	41 8	Straumann	SLA	0	0.38	0.72	100.00%	8
colleagues <sup>158</sup>														
Lee and	2012	×		5.7	175	116	259	Mixed	Mixed	6	0.93	0.15	Unknown	0.1
colleagues													,	
Nickenig and	2013	Д	1: Non polished "	5.2	34	20	70	Nobel Biocare	TiUnite	0	0.70		Unknown	33
colleagues			collar 2: Polished collar	5.2		69	63	Nobel Biocare	TiUnite	C	1.40			'n
Kokovic and	2014	Д	1: Immediate	5	12	36		Straumann	SLA	0	0.40	0.24	100.00%	, rn
colleagues <sup>161</sup>			loading											
			2: Early loading	5		36	36 8	Straumann	SLA	0	0.80	0.19	100.00%	8
Mertens and	2012	×		10.1	14	52		Astra Tech	TiOblast	1	0.30	0.50	100.00%	8
colleagues <sup>162</sup>														
Renvert and colleagues <sup>163</sup>	2012	~	1: TiOblast	13	41	08	7 08	Astra Tech	TiOblast	1	0.80		Unknown	m
0			2: TiUnite	13		84	84	Nobel Biocare	TiUnite	1	1.00		Unknown	3
Mordenfeld and	2014	Ь		10.2	20	53	53	Nobel Biocare	Machined	1	1.60	1.00	86.00%	2
colleagues <sup>164</sup>														

Authorized Hallows, and the control of the control of the control of country and service in the country and service in the control of country and service in the country and service i	Study         Treatment         follow-up at a t implants         mplant at Implant         Implant at Implant         Implant at Implant           2012         R         subgroups         years         baseline follow-up at at Implant         177         Nobel Biocarc           2013         R         a         127         3.7         Nobel Biocarc         technologies           2013         R         a         127         3.3         8.5         SPS desual           2013         R         a         120         3.2         5.3         SPS desual           2013         R         a         120         3.2         5.3         SPS desual           2014         P         a         3.0         5.1         5.0         SPS desual           2015         R         a         4.4         7.2         SPS desual         Implant           2016         R         a         1.1         1.1         2.2         SPS desual         Implant           2017         R         a         1.1         2.2         8.2         SPS desual         Implant           2018         R         B         1.1         1.2         BPS desual         Implant	Table 3. cont.													
Year   Study   Statistical Particle Property   Particle Property   Statistical Particle Parti	Year   Action   Act											Mean	Standard		
No.   Color	New York   Study   Treatment follow-up at at a timplant   Study   Statement follow-up   Acad   Statement follow-up   Acad   Broad					Patients	Implants	Implants			Baseline	implant	deviation	Implant	
Year         design         Subjective         Approximate         Supplementary         Supplementary         Figure         Figure <th>Year         design         subgroups         years         baseline baseline follow-up of plane         brand blocks           2012         R         6.7         68         217         217         Nobel Biocarce technologies           2012         P         39         MKI implant         4.7         39         MKI implant           2013         R         20         52         53         53         58         Nobel Biocarce technologies           2013         R         18         20         52         53         58         Nobel Biocarce technologies           2013         R         18         18         5         44         73         Nobel Biocarce technologies           2012         R         141         22         89         89         Nobel Biocarce technologies           2012         R         141         22         89         89         Nobel Biocarce technologies           2012         R         141         22         89         89         Nobel Biocarce technologies           2013         R         15         21         10         46         17         17         Actar Technologies           2013         R         1         1</th> <th></th> <th>Study</th> <th></th> <th>follow-up</th> <th></th> <th>at</th> <th>at</th> <th>Implant</th> <th></th> <th>radiograph</th> <th>pone</th> <th>pone</th> <th>survival</th> <th>Surface</th>	Year         design         subgroups         years         baseline baseline follow-up of plane         brand blocks           2012         R         6.7         68         217         217         Nobel Biocarce technologies           2012         P         39         MKI implant         4.7         39         MKI implant           2013         R         20         52         53         53         58         Nobel Biocarce technologies           2013         R         18         20         52         53         58         Nobel Biocarce technologies           2013         R         18         18         5         44         73         Nobel Biocarce technologies           2012         R         141         22         89         89         Nobel Biocarce technologies           2012         R         141         22         89         89         Nobel Biocarce technologies           2012         R         141         22         89         89         Nobel Biocarce technologies           2013         R         15         21         10         46         17         17         Actar Technologies           2013         R         1         1		Study		follow-up		at	at	Implant		radiograph	pone	pone	survival	Surface
Marie   Marie   Machine	2012 R			subgroups	years	baseline	baseline f	ollow-up		Surface	time	loss (mm)	loss (mm)	rate %	roughness
2014         P         A control of property	2012         P         3         19         74         39         MIS implant technologies in palasts           2014         P         20         52         53         53         53         587 denal technologies in palasts           2012         R         7         18.5         53         511         511         Straumanm in palasts           2012         R         7         14,1         22         89         89         Nobel Biocare           2012         R         74         73         70         Unknown           2012         R         74         73         70         Unknown           2012         R         74         73         70         Unknown           2013         R         74         73         70         Unknown           2014         R         74         73         70         Unknown           2015         R         74         73         70         Unknown           2016         R         74         73         70         Unknown           2017         R         184         73         Nobel Biocare           2018         R         174         174         <				6.7	89	217		Nobel Biocare	Machined	1	0.26		Unknown	2
101         P         A Company         10         14         50         15         14         15         14         15         14         15         14         16         15         14         16         15         14         15         14         16         15         14         15         14         15         14         15         14         15         14         15	2012         P         5         19         74         39         MIS implant rechnologies service rechnologies service rechnologies services and implants in plants in p	colleagues <sup>165</sup>													
10	18.5   2.5				S	19	74	39	MIS implant	Moderately rough	0	1.41	0.67	Unknown	3
7014         P         Act of the color         S         S         S         S         S         S         Act of the color         Act of the color         P         Act of the color         Act of the co	2014         P         20         52         53         53         51         SPS dental implants           2013         R         18.5         53         62         59         Nobed Biocare implants           2012         R         141         22         89         89         Nobed Biocare implants           2012         R         141         22         89         89         Nobed Biocare implants           2012         R         141         22         89         89         Nobed Biocare implants           2012         R         141         22         89         89         Nobed Biocare implants           2012         R         141         22         89         89         Nobed Biocare implants           2012         R         141         22         89         Nobed Biocare implants         170         Astra Tech           2013         P         1:TrUnite         6.8         18         170         Astra Tech           2014         P         2:Machined         6.8         130         Nobel Biocare           2013         R         1:TrUnite         6.3         47         136         Nobel Biocare           2013	colleagues <sup>166</sup>							technologies						
10   10   10   10   10   10   10   10	18.5   18.5   18.5   18.5   18.5   19.5				20	52	53	53	SPS dental	Rough	6	0.67		73.40%	4
101         R         A         185         55         62         59         Nobel Biscare         Andrhind         1         0.83         1.45         91.30%           102         R         A         301         311         21         80         Nobel Biscare         Minds         1         1.20         0.50         98.80%           201         R         A         44         75         70         Uishawan         1         1.80         1.50         98.90%           201         R         A         44         75         70         Uishawan         1         1.80         1.50         98.90%           201         R         A         44         75         70         Uishawan         9         0.70         1.85         1.50         9.90%           201         R         45         20         10         17         Asan Tach         170base         0         0.70         0.70         0.70         9.90%           201         R         10         15         10         10         1.70         Asan Tach         170base         Mindel Biscare         Mindel Biscare         170base         0         0         0         0	2013         R         18.5         53         62         59         Nobel Biocare           2012         R         10         303         511         511         Straumann           2013         R         14.1         22         89         89         Nobel Biocare           2012         R         13.2         121         108         Nobel Biocare           2013         P         1.TGblast         5         44         73         70         Unknown           2014         P         1.TGblast         5         20         20         15         Zimmer Dental           2013         P         1.TGblast         5         66         184         170         Astra Tech           2014         P         1.TGblast         5         66         184         170         Astra Tech           2012         P         1.TGblast         6         22         20         15         Nobel Biocare           2014         P         1.TGblast         6         22         54         49         Nobel Biocare           2013         R         1.TGblast         6         22         54         49         Nobel Biocare	colleagues <sup>167</sup>							implants						
0.1         R         A. Medined         10         30         51         51         Medinement         11A         12         98         Nédel Bissare         Mindel Bissare	2012         R         10         303         511         511         Straumann           2013         R         14.1         22         89         89         Nobel Biocare           2012         R         7         44         73         70         Unknown           2012         P         13.2         121         108         207         Straumann           2012         R         7         46         108         172         Zimmer Dental           2014         P         1: TrOblast         5         66         184         170         Astra Tech           2013         P         1: TrOblast         5         66         184         170         Astra Tech           2014         R         1: TrUnite         6.8         103         134         Nobel Biocare           2014         R         1: TrUnite         6.8         103         134         Nobel Biocare           2014         P         1: TrUnite         6.8         103         Nobel Biocare           2015         P         1: TrUnite         6.7         47         Nobel Biocare           2013         R         1: TrUnite         6.7         4	;			18.5	53	62	59	Nobel Biocare	Machined	1	0.82	1.45	91.50%	2
2012   R	2012         R         10         303         511         511         Straumann           2013         R         14.1         22         89         89         Nobel Biocare           2012         R         13.2         121         108         207         Straumann           2012         R         13.2         121         108         207         Straumann           2012         R         10         46         108         172         Zimmer Dental           2014         P         1. TrOblast         5         66         184         170         Astra Tech           2013         P         1. TrOblast         5         66         184         170         Astra Tech           2014         P         1. TrOblast         5         66         184         170         Astra Tech           2015         P         1. TrOblast         5         6         184         170         Astra Tech           2014         R         1. TrObles         6.8         103         133         Nobel Biocare           2014         P         1. TrObles         6.8         121         136         Nobel Biocare           2013 <td>colleagues<sup>168</sup></td> <td></td>	colleagues <sup>168</sup>													
101         R         41         21         89         Solde Biscare         Mixed         1         148         120         69         98999           2012         R         44         23         7.0         Uilstoom         175         189         1.89         1.89         1.89         1.89         98,9999           2012         R         44         23         20         1.0 <td< td=""><td>2013         R         14.1         22         89         89         Nobel Biocare           2012         R         5         44         73         70         Unknown           2012         P         132         121         108         72         Straumann           2012         R         100         46         108         172         Simmer Dental           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2014         P         1: TiOhlast         5         66         184         170         Astra Tech           2012         P         1: TiOhlast         5         66         184         170         Astra Tech           2014         R         1: TiUnite         6.8         103         133         105         Nobel Biocare           2013         P         1: TiUnite         6.8         103         134         49         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare</td><td>691</td><td></td><td></td><td>10</td><td>303</td><td>511</td><td>511</td><td>Straumann</td><td>SLA</td><td>0</td><td>1.52</td><td>99.0</td><td>98.80%</td><td>e</td></td<>	2013         R         14.1         22         89         89         Nobel Biocare           2012         R         5         44         73         70         Unknown           2012         P         132         121         108         72         Straumann           2012         R         100         46         108         172         Simmer Dental           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2014         P         1: TiOhlast         5         66         184         170         Astra Tech           2012         P         1: TiOhlast         5         66         184         170         Astra Tech           2014         R         1: TiUnite         6.8         103         133         105         Nobel Biocare           2013         P         1: TiUnite         6.8         103         134         49         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare	691			10	303	511	511	Straumann	SLA	0	1.52	99.0	98.80%	e
1,	2013         R         14.1         22         89         89         Nobel Biocare           2012         R         5         44         73         70         Uhknown           2012         P         13.2         121         108         207         Straumann           2013         R         1         7         6         184         172         Zimmer Dental           2013         P         1         TiOblast         5         66         184         170         Astra Tech           2013         P         1         TiOblast         5         66         184         170         Astra Tech           2013         P         1         TiOblast         5         66         184         170         Astra Tech           2014         R         1         10         24         48         30         Mixed           2014         R         1         10         24         48         30         Mixed           2014         P         1         TiOnite         6         22         54         49         Nobel Biocare           2013         R         1         TiOnite         46 <td< td=""><td>S</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	S													
912         R         44         73         94         104 bitsoon         Christoon         1         185         1.55         95.98%           2012         R         121         102         102         103         17         Stramman         175         1         185         1.55         95.00%           2013         R         46         103         17         Zimmer Denial         Inknown         9         0.73         0.25         95.00%           2013         P         46         104         Astr Tech         Ticknown         9         0.70	2012         R         5         44         73         70         Unknown           2012         P         132         121         108         207         Straumann           2012         R         10         46         108         172         Simmer Dental           2013         P         1: TiOblast         5         20         20         15         Simmer Dental           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2014         R         1: TiOnite         6.8         187         175         Nobel Biocare           2014         R         1: TiUnite         6.8         103         134         154         Nobel Biocare           2013         R         1: TiUnite         6.8         103         134         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         Nobel Biocare           2013         R	es <sup>170</sup>			14.1	22	68	68	Nobel Biocare	Mixed	1	1.80	1.50	98.90%	Mixed
2012         R         132         121         108         2012         175         1         185         153         153         95,00%           2013         P         1         4         10         46         10         172         Zimmer Derial         10 kmon         0         0.18         0.18         95,00%           2013         P         1         TO 4         6         10         172         Zimmer Derial         0         0.18         0.18         95,00%           2013         P         1         TO 4         48         170         Astra Tech         TO blast         0         0.20         0.20         0.20         0.90%           2012         P         1	2012         P         132         121         108         207         Straumann           2014         P         10         46         108         172         Zimmer Dental           2014         P         1: TiOblast         5         20         20         15         Zimmer Dental           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2014         P         1: TiOnite         6.8         103         133         105         Mixed           2014         P         1: TiUnite         6.8         103         133         Nobel Biocare           2013         P         2: Machined         6.8         103         133         Nobel Biocare           2013         P         1: TiUnite         6.8         103         134         49         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare <td></td> <td></td> <td></td> <td>ď</td> <td>44</td> <td>73</td> <td>20</td> <td>Unknown</td> <td>Unknown</td> <td>C</td> <td>1.80</td> <td></td> <td>%06 56</td> <td>Unknown</td>				ď	44	73	20	Unknown	Unknown	C	1.80		%06 56	Unknown
2012         R         132         131         108         307         Streamman         TPS         1 185         155         52.0%           2012         R         2         4         10         46         108         172         Zimmer Denial         10         0.18         0.18         9.00%           2013         P         1. TOMblast         5         20         15         1.20         Astra Tech         TOMblast         0         0.18         9.500%           2013         P         1. TOMblast         1         1. S         1. TOMblast         0         0.70         0.20         0.20         9.500%           2014         R         1. S         1. S         Astra Tech         TOMblast         0         0.70         0.20         0.20         9.500%           2014         R         1. S         1. S         Nodel Biocare         TAbritand         0         0.70         0.70         0.20         9.500%           2014         R         1. TOMblast         1. S         1. S         1. S         Nodel Biocare         TAbritand         0         0.70         0.70         0.20         9.50%           2013         R         1. TOMbla	2012         P         13.2         121         108         207         Straumann           2013         R         10         46         108         172         Zimmer Denial           2014         P         1: TiOblast         5         66         184         170         Astra Tech           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2012         P         2: Machined         5         66         184         170         Astra Tech           2014         R         1: TiOnite         6.8         103         133         133         Nobel Biocare           2013         P         2: Machined         6.8         103         134         Nobel Biocare           2013         P         2: Machined         6.8         103         136         Nobel Biocare           2013         R         1: TiOnite         6.7         47         136         Nobel Biocare           2013         R         1: TiOnite         8.2         52         Nobel Biocare           2013         R         1: TiOnite         8         71         74         Nobel Biocare	_			ò		2	2				2017			
2013         R         11 Oblish         46         108         172         Zimmer Denial         Utknown         9         0.18         9         99,00%           2013         P         1: TOblist         5         20         20         15         Zimmer Denial         Utknown         9         0.18         9,900%         94,00%           2013         P         1: TOblist         5         66         184         170         Astra Tech         Toblists         0         0.70         0.40         9,40%           2014         R         1, Machinel         6.8         1, 1         Nobel Biocare         TiVinite         9         0,40         0,40         9,40%           2014         R         1, 1         Nobel Biocare         TiVinite         9         1,20         0,40         9,40%           2014         R         1, 2         1, 3         Nobel Biocare         TiVinite         9         0,70         0,30         9,40%           2013         R         1, 3         Nobel Biocare         TiVinite         0         0,70         0,30         9,40%           2013         R         1, 3         1, 4         1, 4         1, 4         Nobel Biocar	2012         R         10         46         108         172         Zimmer Dental           2014         P         1: TiOblast         5         20         20         15         Zimmer Dental           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2012         P         2: Machined         5         66         184         170         Astra Tech           2014         R         1: TiUnite         6.8         103         133         133         Nobel Biocare           2014         P         2: Machined         6.8         103         133         133         Nobel Biocare           2013         P         2: Machined         6.8         103         134         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         14         Nobel Biocare           2012         P         1: Delayed         10         48         84				13.2	121	108	207	Straumann	TPS	-	1.85	1.55	92.30%	4
2012         R         1         46         108         172         Zimmer Denial Unknown         Unknown         9         0.18         0.18         99,00%           2013         P         11 TOblast         5         66         184         176         Artir Tech         TOblast         0         0.26         9,400%           2012         P         2 Machined         5         66         184         176         Mixed         Machined         0         0.40         9         9,400%         9,400%           2014         R         1, TUblite         6         184         176         Mixed         Machined         0         0.40         9,400%         9,400%           2013         R         1, TUblite         6         13         13         Nobel Biocare         110int         0         0         0         0         0         9,400%         9	2012         R         10         46         108         172         Zimmer Dental Expental Expensal           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2012         P         2: Machined         5         66         184         175         Nobel Biocare           2014         R         1: TiUnite         6.8         103         133         134         Nobel Biocare           2014         P         2: Machined         6.8         103         133         133         Nobel Biocare           2012         P         2: Machined         6.8         103         134         49         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: Delayed         10         48	ues <sup>172</sup>													
2014         P         F         20         15         Zimner Denal         Unknown         0         0.20         0.26         94,00%           2013         P         1: TOklast         5         6         184         170         AstraTech         Toklast         0         0.70         0.70         9,40%           2014         P         - Machined         5         6         184         170         AstraTech         Inchined         0         0.40         9,40%         9,50%         9,40%         9,50%         9,40%         9,50%         9,40%         9,50%         9,40%         9,50%         9,40%         9,50%         9,40%         9,50%         9,40%	2014         P         1: TiOblast         5         20         20         15         Zimmer Dental           2013         P         1: TiOblast         5         66         184         170         Astra Tech           2012         P         2: Machined         5         6.8         187         175         Nobel Biocare           2014         R         1: TiUnite         6.8         103         133         133         Nobel Biocare           2012         P         2: Machined         6.8         22         54         49         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: Delayed         10         48         84         Nobel Biocare           2012         Palacement         10         48         84         Nobel B				10	46	108	172	Zimmer Dental	Unknown	6	0.18		%00.66	Unknown
2013         P         1: TOblast         5         66         184         170         Astra Tech         TrOblast         0         070         070         95,00%           2012         P         2: Machined         5         187         175         Nobel Biscare         TrUnite         0         0.40         94,70%         94,70%           2014         R         10         24         48         30         Mixed         Moderately rough         9         120         94,70%         95,00%           2014         R         15         154         154         154         154         170 in         9         20         0.40         94,70%           2014         R         15         154	2013         P         1: TfOblast         5         66         184         170         Astra Tech           2012         P         2: Machined         5         6.8         187         175         Nobel Biocare           2014         R         1: TfUnite         6.8         103         133         134         Nobel Biocare           2014         P         2: Machined         6.8         103         133         133         Nobel Biocare           2013         R         1: TfUnite         6.7         22         54         49         Nobel Biocare           2013         R         1: TfUnite         6.7         47         136         Nobel Biocare           2013         R         1: TfUnite         6.7         47         136         Nobel Biocare           2013         R         1: TfUnite         6.7         47         136         Nobel Biocare           2013         R         1: Delayed         10         48         84         Nobel Biocare           2012         P         1: Delayed         10         48         84         Nobel Biocare           2012         P         1: Delayed         10         74         Nobel				5	20	20	15	Zimmer Dental	Unknown	0	0.70	0.26	94.00%	Unknown
2013         P         1: TiOblast         5         66         184         170         Asta Tech         TiOblast         0         0.40         0.40         9500%           2012         P         2. Machined         5         48         30         Mixed         Moderately rough         9         1.20         94.70%           2013         R         1.3         Nobel Biscare         TiUnite         6.8         103         133         Nobel Biscare         TiUnite         9         1.80         0.80         94.70%           2013         R         1.3         Nobel Biscare         TiUnite         0         0.75         0.47         97.90%           2013         R         1.2         1.3         Nobel Biscare         TiUnite         0         0.75         0.47         97.90%           2013         R         1.2         1.2         1.2         1.0         Nobel Biscare         TiUnite         0         0.75         0.47         97.90%           2013         R         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2         1.2	2013         P         1: TiOblast         5         66         184         170         Astra Tech           2012         P         2: Machined         5         187         175         Nobel Biocare           2014         R         1: TiUnite         6.8         103         133         134         Nobel Biocare           2014         P         2: Machined         6.8         103         133         133         Nobel Biocare           2013         P         2: Machined         6.7         46         121         106         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: Delayed         10         48         84         Nobel Biocare           2012         Palacement         10         74         74         Nobel Biocare	colleagues <sup>174</sup>													
2014         R         2 Machined         5         187         173         Nobel Biocare         Machined         0         040         9         9470%           2014         R         1         48         30         Mixed         Moderately mogh         9         120         690         99,470%           2014         R         1         154         154         154         Nobel Biocare         TiUnite         9         120         690         99,470%           2014         P         Adachined         6.8         13         Nobel Biocare         TiUnite         0         0.76         0,47         99,20%           2012         P         12         14         9         Nobel Biocare         TiUnite         0         0.76         0,47         99,20%           2013         R         1         16         16         13         Nobel Biocare         TiUnite         0         0.76         0,47         99,20%           2013         R         1         16         16         13         Nobel Biocare         TiUnite         0         0.63         0,47         99,20%           2013         R         1         14         7	2012 P			1: TiOblast	S	99	184	170	Astra Tech	TiOblast	0	0.70		95.00%	3
2014 R R I: T.Unite 6.8	2012 P	colleagues <sup>175</sup>													
2014 R I: TiUnite 6.8 134 48 30 Mixed Moderately rough 9 120 9550%	2012         P         10         24         48         30         Mixed           2014         R         1: TIUnite         6.8         103         133         134         Nobel Biocare           2014         P         2: Machined         6.8         103         133         133         Nobel Biocare           2013         P         1: TIUnite         6.7         46         121         106         Nobel Biocare           2013         R         1: TIUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: Delayed         10         48         84         Nobel Biocare           2012         P         1: Delayed         10         48         84         Nobel Biocare           2012         P         1: Delayed         10         74         Nobel Biocare			2: Machined	Ŋ		187	175	Nobel Biocare	Machined	0	0.40		94.70%	2
2014         R         1: TiUnite         6.8         154         154         154         Nobel Biocare         TiUnite         9         2.00         0.90         99,40%           2014         P         2. Machined         6.8         103         133         133         Nobel Biocare         TiUnite         0         0.76         0.47         97,96%           2012         P         2. Machined         6.7         46         121         106         Nobel Biocare         TiUnite         0         0,70         1.35         99,20%           2013         R         1: TiUnite         6.7         47         136         136         Nobel Biocare         TiUnite         0         0,70         1.35         99,20%           2013         R         3. Machined         8.2         5         5         Nobel Biocare         TiUnite         0         0.70         1.35         98,39%           2013         R         3. Machined         8         71         74         5         Straumann         Thys         0         0.63         0.68         98,39%           2013         R         3. Machined         1         74         74         Straumann         Thys	2014 R I: TiUnite 6.8 103 133 134 Nobel Biocare 2014 P 6.8 103 133 133 Nobel Biocare 2012 P 10 10 10 10 10 10 10 10 10 10 10 10 10				10	24	48		Mixed	Moderately rough	6	1.20		95.50%	3
2014         R         I: TiUnite         6.8         154         154         Nobel Biocare         TiUnite         9         2.0         0.90         99-40%           2014         P         2. Machined         6.8         133         133         Nobel Biocare         TiUnite         0         0.70         0.36         94-70%           2012         P         22         54         49         Nobel Biocare         TiUnite         0         0.70         1.35         95-20%           2013         R         13         136         Nobel Biocare         TiUnite         0         0.70         1.35         95-20%           2013         R         13         136         136         Nobel Biocare         TiUnite         0         0.70         1.35         96-25%           2013         R         13         136         136         Nobel Biocare         TiUnite         0         0.63         0.43         96-15%           2013         R         12         14         74         Straumann         TPS         0         0         0         0         0         0         0         0         0         0         0         0         0         0<	2014         R         1: TiUnite         6.8         103         134         154         Nobel Biocare           2014         P         2: Machined         6.8         103         133         133         Nobel Biocare           2012         P         22         54         49         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: TiUnite         6.7         47         136         Nobel Biocare           2013         R         1: Delayed         10         48         84         Nobel Biocare           2012         P         1: Delayed         10         48         84         Nobel Biocare           2012         P         1: Delayed         10         48         84         Nobel Biocare	colleagues <sup>176</sup>													
2014 P 2 Machined 6.8 103 133 Nobel Biocare Machined 9 1.80 0.80 94,70% 2.012 P 34 49 Nobel Biocare TiUnite 6 22 54 49 Nobel Biocare TiUnite 6.7 47 136 121 106 Nobel Biocare TiUnite R 1.1TUnite 6.7 47 136 136 Nobel Biocare TiUnite R 2.42 0.74 98.39% 2.013 R 2.013 R 34 84 Nobel Biocare TiUnite R 3.1	2014 P			1: TiUnite	6.8		154	154	Nobel Biocare	TiUnite	6	2.00	0.90	99.40%	E
2. Machined         6.8         103         133         Nobel Biocare         Machined         9         1.80         0.80         94.70%           2014         P         2. Machined         6         2.2         54         49         Nobel Biocare         TiUnite         0         0.76         0.47         97.96%           2013         R         1. TiUnite         6.7         46         121         106         Nobel Biocare         TiUnite         0         0.70         1.35         99.20%           2013         R         1. TiUnite         6.7         47         136         Nobel Biocare         Machined         1         2.42         0.34         96.15%           2013         R         2.31         2.31         Straumann         SLA         0         0.63         0.68         98.30%           2013         R         74         74         Straumann         TPS         0         1         1         10.00%           2012         Palcaenett         10         48         84         Nobel Biocare         TiUnite         0         0         0.37         0.40         98.05%           2012         Palcaenett         1         74	2014 P 2. Machined 6.8 103 133 133 Nobel Biocare 6 2 2 54 49 Nobel Biocare 10 Nobel Replace 10 10 46 121 106 Nobel Biocare 10 Nobel Biocare 10 10 168 231 231 Straumann 10 168 231 231 231 231 231 231 231 231 231 231	colleagues <sup>177</sup>													
2014         P         6         22         54         49         Nobel Replace         TiUnite         0         0.76         0.47         97.96%           2012         P         10         46         121         106         Nobel Biocare         TiUnite         0         0.70         1.35         99.20%           2013         R         1:TiUnite         6.7         47         136         Nobel Biocare         TiUnite         1         1.53         0.25         99.20%           2013         R         2:Machined         8.2         52         Nobel Biocare         Machined         1         1.53         0.63         0.68         98.30%           2013         R         74         74         Straumann         TPS         0         0.63         0.68         98.30%           2012         P         1:Delayed         10         48         84         Nobel Biocare         TiUnite         0         1.93         0.40         98.29%           2012         P         1:Delayed         10         48         84         Nobel Biocare         TiUnite         0         0         0         0         0         0         0         0         0	2012 P 10 hobel Replace  2013 R 1: TiUnite 6.7 47 136 136 Nobel Biocare  2013 R 2: Machined 8.2 52 52 Nobel Biocare  2013 R 8 71 74 74 Straumann  2013 R 8 71 74 Nobel Biocare  placement 10 48 84 84 Nobel Biocare  2012 P 1: Delayed 10 48 84 Nobel Biocare  2013 P 2: Impactment 74 74 Nobel Biocare			2: Machined	6.8	103	133	133	Nobel Biocare	Machined	6	1.80	0.80	94.70%	2
2012 P 1: TiUnite 6.7 47 136 Nobel Biocare TiUnite 6.7 47 136 Nobel Biocare TiUnite 6.7 47 136 Nobel Biocare TiUnite 7.2 Machined 8.2 52 52 Nobel Biocare Machined 8.2 71 74 74 Straumann 7FS 0 1.93 0.40 98.05% 1 100.00% 1.93 0.40 98.05% 2013 R 21 231 Straumann 7FS 0 1.93 0.40 98.05% 1 100.00% 1.93 0.40 98.05% 2013 R 21 100.00% 1.94 Nobel Biocare TiUnite 0 1.98 0.37 96.52% 96.52%	2012 P 10 46 121 106 Nobel Biocare 2013 R 1: TiUnite 6.7 47 136 136 Nobel Biocare 2013 R 2: Machined 8.2 52 52 Nobel Biocare 2013 R 71 74 74 Straumann 2012 P 1: Delayed 10 48 84 84 Nobel Biocare placement 10 74 74 Nobel Biocare absocared 10 74 74 Nobel Biocare	9			9	22	54	49	Nobel Replace	TiUnite	0	0.76	0.47	92.96%	E
2012 P 10 46 121 106 Nobel Biocare TiUnite 6.7 47 136 136 Nobel Biocare TiUnite 1 1.53 0.25 99.20%  2013 R 1: TiUnite 6.7 47 136 136 Nobel Biocare TiUnite 1 1.53 0.25 98.53%  2013 R 231 231 Straumann SIA 0 0.63 0.68 98.30%  2013 R 34 84 Nobel Biocare TiUnite 0 1.93 0.40 98.05%  2014 P 1: Delayed 10 48 84 Nobel Biocare TiUnite 0 1.98 0.37 96.52%  2015 P 2016 P 3.5	2012 P 100 46 121 106 Nobel Biocare 2013 R 1: TiUnite 6.7 47 136 136 Nobel Biocare 2013 R 2: Machined 8.2 52 52 Nobel Biocare 2013 R 8 71 74 74 Straumann 2013 R 8 71 74 Straumann 2012 P 1: Delayed 10 48 84 Nobel Biocare placement 10 74 74 Nobel Biocare														
2013 R I: TiUnite 6.7 47 136 Nobel Biocare TiUnite 1 1.53 0.25 98.53%  2013 R 2: Machined 8.2 52 Nobel Biocare Machined 1 2.42 0.34 96.15%  2013 R 201	2013 R I: TiUnite 6.7 47 136 136 Nobel Biocare 2013 R 2. Machined 8.2 52 52 Nobel Biocare 2013 R 71 74 74 Straumann 2012 P I: Delayed 10 48 84 84 Nobel Biocare placement 10 74 74 Nobel Biocare	170			10	46	121	901	Nobel Biocare	TiUnite	0	0.70	1.35	99.20%	ю
2013 R I: TiUnite 6.7 47 136 136 Nobel Biocare TiUnite 1 1.53 0.25 98.53%  2013 R 231 231 Straumann SLA 0 0.63 0.68 98.39%  2013 R 371 74 74 Straumann TPS 0 1.93 0.40 98.05%  2014 P I: Delayed 10 48 84 84 Nobel Biocare TiUnite 0 1.98 0.37 96.52%  2015 P I: Delayed 10 74 74 Nobel Biocare TiUnite 0 1.98 0.37 96.52%	2013 R I: TiUnite 6.7 47 136 136 Nobel Biocare 2013 R 2013 R 71 74 74 Straumann 2013 P I: Delayed 10 48 84 Nobel Biocare 2012 P 2: Immediate 10 74 Nobel Biocare absorbant														
2013 R 2. Machined 8.2 52 Nobel Biocare Machined 1 2.42 0.34 96.15% 2013 R 201 168 231 231 Straumann SLA 0 0.63 0.68 98.30% 2013 R 371 74 74 Straumann TPS 0 1.93 0.40 98.05% 2012 P 1: Delayed 10 48 84 Nobel Biocare Ti'Unite 0 1.93 0.40 98.05% 2012 P 2: Immediate 10 74 74 Nobel Biocare Ti'Unite 0 1.98 0.37 96.52%	2013 R 10 belyed 8.2 52 Nobel Biocare 10 168 231 231 Straumann 2013 R 71 74 74 Straumann 2012 P 1: Delayed 10 48 84 84 Nobel Biocare placement 2: Impedate 10 74 Nobel Biocare placement 10 74 74 74 74 Nobel Biocare placement 10 74 74 74 74 Nobel Biocare placement 10 74 74 74 74 74 74 74 74 74 74 74 74 74			1: TiUnite	6.7	47	136	136	Nobel Biocare	TiUnite	-	1.53	0.25	98.53%	ю
2013 R 2. Machined 8.2 52 Nobel Biocare Machined 1 2.42 0.34 96.15% 2013 R 2013 R 3.1 Straumann SLA 0 0.63 0.68 98.30% 2013 R 371 74 74 Straumann TPS 0 1.93 0.40 98.05% 2012 P 1: Delayed 10 48 84 Nobel Biocare TijUnite 0 1.93 0.40 98.05% 2012 P and the straumann TPS 0 1.93 0.40 98.05% 2012 P and the straumann TPS 0 1.98 0.37 96.52% 2012 P and the straumann TPS 0 1.98 0.37 96.52% 2013 P and the straumann TPS 0 1.98 0.37 96.52%	2013 R 2. Machined 8.2 52 Nobel Biocare 2013 R 10 168 231 231 Straumann 2013 R 77 74 74 Straumann 2012 P 1: Delayed 10 48 84 84 Nobel Biocare placement 10 74 74 Nobel Biocare 2012 P 2: Inmediate 10 74 74 Nobel Biocare 2012 P 3: Inmediate 2: Inmediate 3: Inmediate 2: Inmediate 3: Inmediate 3	colleagues <sup>180</sup>													
2013 R 201	2013         R         10         168         231         231         Straumann           2013         R         71         74         74         74         Straumann           2012         P         1: Delayed         10         48         84         84         Nobel Biocare           placement         2: Immediate         10         74         74         Nobel Biocare			2: Machined	8.2		52	52	Nobel Biocare	Machined	-	2.42	0.34	96.15%	2
2012 P I: Delayed 10 48 84 Nobel Biocare Ti'Unite 0 1.93 0.40 98.05% placement 2: Immediate 10 74 Nobel Biocare Ti'Unite 0 1.98 0.37 96.52%	2012 P I: Delayed 10 48 84 84 Nobel Biocare placement 10 74 74 Nobel Biocare 2012 P IIImmediate 10 74 74 Nobel Biocare 2: Immediate 10 74 74 Nobel Biocare				10	168	231		Straumann	SLA	0	0.63	0.68	98.30%	3
Silva 2012 P 1: Delayed 10 48 84 84 Nobel Biocare Ti'Unite 0 1.93 0.40 98.0596 placement 2: Innmediate 10 74 74 Nobel Biocare Ti'Unite 0 1.98 0.37 96.5296	2012 P 1: Delayed 10 48 84 84 Nobel Biocare placement 10 74 74 Nobel Biocare 2: Immediate 10 74 74 Nobel Biocare				∞	71	74		Straumann	TPS	0	1		100.00%	4
2012 P 1: Delayed 10 48 84 84 Nobel Biocare TiiUnite 0 1.93 0.40 98.0596 slass placement 2: Innmediate 10 74 74 Nobel Biocare TiiUnite 0 1.98 0.37 96.5296 placement	2012 P 1: Delayed 10 48 84 84 Nobel Biocare placement 10 74 74 Nobel Biocare	colleagues <sup>182</sup>													
Placement 2: Immediate 10 74 74 Nobel Biocare TiUnite 0 1.98 0.37 96.52% placement	placement 2: Immediate 10 74 74 Nobel Biocare			1: Delayed	10	48	84	84	Nobel Biocare	TiUnite	0	1.93	0.40	98.05%	ю
10 74 74 Nobel Biocare TiUnite 0 1.98 0.37 96.52%	10 74 74 Nobel Biocare	colleagues <sup>183</sup>		placement											
placement	nlacement			2: Immediate	10		74	74	Nobel Biocare	TiUnite	0	1.98	0.37	96.52%	8
	Machinette			placement											

Table 3. cont.	nt.												
			Mean	Patients	Mean Patients Implants Implants	mplants			Baseline	Mean implant	Standard deviation	Implant	
	Study	/ Treatment	follow-up	at	at	at	Implant		radiograph	pone	pone	survival	Surface
Author	Year design	n subgroups	years	baseline	baseline baseline follow-up	dn-wollo	brand	Surface	time	loss (mm)	loss (mm)	rate %	roughness
Levine and	2012 P		5	20	21	21	Straumann	SLA	0	0.58		100.00%	3
colleagues <sup>184</sup>													
	2012 P	1: Immediate	5	22	34	26	Straumann	SLA	-	2.20	0.90	Unknown	3
colleagues <sup>185</sup>		placement											
		2: Delayed	2		34	26	Straumann	SLA	-	2.10	1.00	Unknown	E
Heechl and	2013 D	placement	01	30	30	130	Vivo	Vivo	-	08	9 6 5	%08 30%	_
186 SS			0	00	R		VIVE	PATA C	4	1.00	60.0	20.50%0	t
	2011 P		5	14	09	54	Straumann	SLA	1	0.77	0.66	96.70%	8
187													
	2013 P		5	39	156	152	Xive	Xive	0	1.44	0.78	99.40%	4
colleagues <sup>188</sup>													
	2013 R		2	83	501	106	Biomet/3I	Osseotite	0	1.57	1.10	92.10%	2
colleagues <sup>189</sup>													
	2012 P	1: Early loading	7	26	24	24	Nobel Biocare	TiUnite	0	1.29	0.20	100.00%	8
colleagues <sub>190</sub>													
		2: Delayed loading	DD 1	,	24	24	Nobel Biocare	TiUnite	0	1.33	0.20	100.00%	т I
	2013 P		7	38	102	73	Nobel Biocare	TiUnite	0	1.51	1.00	97.10%	m
colleagues.	2013 B		ư	33	376	376	Unbnoum	Habaam	c	1 08		94 90%	Tubnomn
192 SS			0	900	0/6		CHINIDALI	Olivilowii	Þ	1.70		24.5070	Ollkilowii
	2011 P		5	64	98	83	Certain Prevail 3i Osseotite	Osseotite	0	0.97	0.39	97.10%	2
and													
colleagues <sup>193</sup>													
	2013 R	1: Completely	2	264	447	162	Nobel Biocare	Mixed	-	0.60	0.46	94.90%	Mixed
colleagues <sup>194</sup>		edentulous											
		maxilla											
		2: Completely	2		644	219	Nobel Biocare	Mixed	-	0.60	0.47	100.00%	Mixed
		edentulous											
		mandible											
		3: Partially edentu-	1- 5		146	28	Nobel Biocare	Mixed	-	0.60	0.47	%09.26	Mixed
		lous maxilla			;				,		į		
		4: Partially edentu-	-1-		119	69	Nobel Biocare	Mixed	-	0.40	0.50	100.00%	Mixed
Cockill and	D 1100	ious manurore	u	17	150	150	Mixad	Missed	-	00 0		00 740%	Missad
26185			C.	17	601		MIXEG	MIXEG	-	66.0		90.74%	Daring
	2011 P		S	200	626	542	Straumann	TPS	-	0.18	0.88	99,40%	4
961													
	2011 P		∞	17	106	66	Astra Tech	TiOblast	1	0.30	0.72	99.00%	3
colleagues <sup>197</sup>													
								1					

Table 3. cont.	ont.													
											Mean	Standard		
				Mean	Mean Patients Implants Implants	nplants I	mplants			Baseline	implant	deviation	Implant	
		Study	Study Treatment follow-up at	follow-up		at	at	Implant		radiograph	pone	pone	survival	Surface
Author	Year	design	Author Year design subgroups years baseline baseline follow-up brand	years	baseline b	aseline fo	dn-wolle	brand	Surface	time	loss (mm)	loss (mm) ssol	rate %	rate % roughness
Roccuzzo and 2012	2012	Ь	1: Periodontally	10	112	61	59	Straumann	TPS	0	0.75	0.88	%09.96	4
colleagues <sup>198</sup>			healthy											
			2: Moderately peri-	10		95	88	Straumann	TPS	0	1.14	1.11	92.70%	4
			odontally											
			compromised											
			3: Severely peri-	10		06	81	Straumann	TPS	0	0.98	1.22	%00.06	4
			odontally											
			compromised											

pocket depth ranged from 4 to 6 mm. However, only 19/27 papers reported bleeding on probing, 16/27 reported probing depth, and only 11/27 actually defined peri-implantitis.

# **Implant Survival**

From the 87 included papers and 123 study groups, the survival was reported in 79 papers and 107 study groups and ranged between 73.4% and 100%. Figure 1, A–C summarizes the implant survival rate and corresponding function time for the three surface roughness groups. In 44% of the studies the implant survival rate was between 95% and 100%, in half of the studies the survival ranged between 90% and 94.9%. Only in 6% of the studies the survival was below 90% with 73.4% survival after 20 years being the lowest one with a porous titanium alloy implant having a rough surface. The average weighted implant survival was 97.3% including all studies and 96.4% for rough (Figure 1A), 98.4% for moderately rough (Figure 1B), and 97.6% for minimally rough (Figure 1C).

## Bone Loss and Surface Roughness

Of the 123 treatment groups, 21 treatment groups were treated with a minimally rough implant surface (0.5–1  $\mu$ m), 52 treatment groups with a moderately rough implant surface (1–2  $\mu$ m), and 31 treatment groups with a rough implant surface (>2  $\mu$ m); 19 groups reported a mixture of implants or did not report the surface. There were no studies with smooth surfaces available because these were merely experimental surfaces not used in the clinic.

Implant roughness and/or implant system were not reported or unknown and hence all these studies/ treatment groups were considered as a separate group. 134,137,142,171,174,192 Some papers presented in their results a mixture of implants with various surface roughnesses and did not make specific distinction between them and therefore were also excluded for the detailed roughness versus bone loss evaluation. 113,126,128,157,159,170,193–195 Additionally, studies which did not mention the standard deviation of bone loss were excluded because calculation of proportions of bone loss was impossible. 124,147,160,163,165,167,171,175,176,182


Figure 2, A–C summarize the bone loss in relation to the follow-up time including all 87 studies of this review. The overall mean bone loss was 1.01 mm

TABLE 4 Studies Discussing Mean Bone Loss (expressed as positive value in mm) and Standard Deviation, Survival Rate (%), Mean Probing Pocket Depth (mm), Bleeding on Probing (%) and Self-Reported Peri-Implantitis Prevalence

Author	Mean bone loss (SD)	Survival rate	Mean probing pocket depth (mm)	ВоР	Prevalence peri-implantitis
Vandeweghe and colleagues 2016b <sup>117</sup>	1.41 (0.92)	97.00%	3.64		4.10%
Nedir and colleagues 2016 <sup>118</sup>	1.00 (0.90)	100.00%	_		8.70%
van Velzen and colleagues 2015 <sup>125</sup>	1.21 (0.94)	99.70%	3.71		7.00%
Trullenque & Guisado 2014 <sup>126</sup>	1.84 (1.35)	90.60%	_		21.00%
Meijer and colleagues 2014 <sup>128</sup>	1.10 (1.10)	95.30%	3.4		20.30%
Schropp and colleagues 2014 <sup>130</sup>	0.67 (0.98)	_	_	70.00%	4.30%
Mangano and colleagues 2015 <sup>134</sup>	1.80 (0.60)	97.20%	_		1.10%
Simion and colleagues 2015 <sup>135</sup>	1.34 (0.79)	93.20%	2.9	54.00%	0.00%
Meyle and colleagues 2014 <sup>140</sup>	0.60 (0.26)	96.30%	3.3	27.00%	23.80%
Anitua and colleagues 2014 <sup>142</sup>	0.95 (0.65)	98.90%	_		0.90%
Donati and colleagues 2015 <sup>146</sup>	0.32 (1.15)	95.60%	_	13.00%	2.90%
Gelb and colleagues 2013 <sup>151</sup>	1.49 (1.03)	100.00%	_	4.70%	0.00%
Schwarz and colleagues 2014 <sup>152</sup>	1.10 (1.20)	89.20%	_	60.00%	4.30%
Chappuis and colleagues 2013 <sup>39</sup>	0.14 (1.09)	89.50%	3.14		6.30%
Renvert and colleagues 2012 <sup>163</sup>	0.80 (-)	_	_	80.00%	32.10%
č	1.00 (-)	_	_	94.00%	39.70%
Frisch and colleagues 2013 <sup>170</sup>	1.80 (1.50)	98.90%	3.13	21.00%	8.00%
Camargos and colleagues 2012 <sup>171</sup>	1.80 (-)	95.90%	2.3	59.00%	4.30%
Lops and colleagues 2012 <sup>172</sup>	1.85 (1.55)	92.30%	2.3		8.30%
Ormianer and colleagues 2012 <sup>173</sup>	0.18 (-)	99.00%	_		2.30%
Ravald and colleagues 2013 <sup>175</sup>	0.70 (-)	95.00%	_		6.00%
Ü	0.40 (-)	94.70%	_		5.00%
Jungner and colleagues 2014 <sup>177</sup>	2.00 (0.90)	99.40%	1.8		1.80%
Ostman and colleagues 2012 <sup>179</sup>	0.70 (1.35)	99.20%	_	9.20%	1.00%
Arnhart and colleagues2013 <sup>180</sup>	2.42 (0.34)	96.20%	2.86	23.20%	1.90%
Lai and colleagues 2013 <sup>181</sup>	0.63 (0.68)	98.30%	_		2.00%
Levine and colleagues 2012 <sup>184</sup>	0.58 (-)	100.00%	_		0.00%
Rodrigo and colleagues 2012 <sup>185</sup>	2.20 (0.90)	_	_	14.20%	8.80%
3	2.10 (1.00)	_	_	13.70%	2.90%
Roccuzzo and colleagues2012 <sup>198</sup>	0.75 (0.88)	96.60%	3.1	12.00%	4.70%
	1.14 (1.11)	92.70%	3.5	31.00%	11.20%
	0.98 (1.22)	90.00%	3.9	31.00%	15.10%

(95% CI 1.00–1.03; SD 0.89 and ranging between −0.94 and 3.47 mm). In the total material, 49% of the implants lost more than 1 mm bone, 18% of the implants lost more than 2 mm, and but 5% lost more than 3 mm bone. A distinction was made per implant surface roughness and shown in Figure 3, A–C for rough, moderately or minimally rough surfaces and Figure 3D for the mixed/unknown surfaces. The mean bone loss, standard deviation and proportion of implants losing more than 1, 2, or 3 mm bone is

given per study. Table 5 shows per surface roughness the mean bone loss pointing to 1.04 mm, 1.01 mm, and 0.86 mm for the rough, moderately, and minimally rough surfaces, respectively. Between minimally and moderately or rough there was a statistically significant difference, but this was not observed between moderately and rough surfaces. Taking bone loss above 2 mm as arbitrary cut-off point reflecting a higher chance for peri-implant disease, the proportion was 20% for rough (Figure 3A), 18% and for



**Figure 1** A. Implant survival in relation to loading time and surface roughness for rough surface implants. B. Implant survival in relation to loading time and surface roughness for moderately rough surface implants. C. Implant survival in relation to loading time and surface roughness for minimally rough surface implants.

moderately rough (Figure 3B), and 14% for minimally rough (Figure 3C).


Unfortunately among the 87 selected papers for this review, there was only one prospective study that compared machined minimally rough Brånemark implants with moderately rough TiUnite implants in conjunction with immediate loading. The TiUnite surface yielded a superior cumulative implant survival of 95.5% compared to 85.5% in the machined group but the corresponding 1.4 and 1.7 mm bone loss was not statistically different. Unfortunately, this study did not report the standard deviation of the mean bone loss and hence could not be included in prevalence calculation.

There are four retrospective studies in this review that compared implants with comparable design, often from the same implant brand, but with different surface roughness. 117,154,177 Vandeweghe and colleagues 117 evaluated 197 Southern Implants with either smooth or minimally rough surface after 10 to 21 years of loading with the

baseline at time of implant placement. Multivariate analysis demonstrated that the rougher surface yielded more peri-implant bone loss than the smooth surface implant. Prevalence of bone loss above 3 mm, as reported in Figure 3, B and C, was 20% versus 4%. Nevertheless, when combining bleeding and probing depth in the analysis only 4.1% of the implants were diagnosed with peri-implantitis. The other three studies and four study groups compare TiUnite moderately rough with machined minimally rough Brånemark implants.

#### Patient-Related Risk Factors

In the smoking group of the Sayardoust study,<sup>154</sup> as well as in the Arnhart study,<sup>180</sup> TiUnite showed a better outcome whereas in the Sayardoust the non-smokers group and the Jungner group<sup>177</sup> the machined implants led to less bone loss. In the study of Arnhart<sup>180</sup> 72% of the patients reported to smoke and also had a history of periodontal disease. This could also explain 89% of the machined surface implants with bone loss above



**Figure 2** A. Bone loss (expressed as positive value in mm) in relation to loading time for rough surface implants. B. Bone loss (expressed as positive value in mm) in relation to loading time for moderately rough surface implants. C. Bone loss (expressed as positive value in mm) in relation to loading time for minimally rough surface implants.




Figure 3 A. Clinical studies and bone loss (expressed as positive value in mm) for rough surface implants including proportions of implants with bone loss above 1, 2, or 3 mm. B. Clinical studies and bone loss (expressed as positive value in mm) for moderately rough surface implants including proportions of implants with bone loss above 1, 2, or 3 mm. C. Clinical studies and bone loss (expressed as positive value in mm) for minimally rough surface implants including proportions of implants with bone loss above 1, 2, or 3 mm. D. Clinical studies and bone loss (expressed as positive value in mm) for unknown/mixed surface implants including proportions of implants with bone loss above 1, 2, or 3 mm.

2 mm. For the meta-analysis the Arnhart study<sup>180</sup> was excluded because of the synergistic effect of smoking and periodontal history in a majority of cases.

Some papers assessed bone loss around similar implants and roughness in patients with various periodontal conditions. Roccuzzo and colleagues<sup>198</sup> demonstrated that periodontally healthy patients lost significantly less bone compared to patients with a history of moderate or severe periodontal disease. This outcome was also reflected by 8% versus 20% to 22% of the implants with bone loss above 2 mm, as can be seen in Figure 3A. Rasperini and colleagues<sup>143</sup> compared machined Brånemark surfaces and Straumann TPS surfaces after 10 years of function in four patient groups being either periodontally healthy or periodontally compromised and with or without smoking as cofactor (Figure 3, A and C). Bone loss above 2 mm was found in 89% to 95% of the implants placed in smokers, irrespective of the implant surface or the periodontal condition and in

78% of both implant types in periodontally compromised non-smoking patients. In the periodontally healthy and non-smokers, the TPS surface yielded 45% of the implants above 2 mm bone loss compared to only 7% in the machined smooth group. It seems that patient related risk factors affect bone loss to a bigger extent than surface roughness.

### Meta-Analysis of Data

Heterogeneity. The estimated amount of total heterogeneity  $t^2$  of all included study groups was equal to 0.54 (SE = 0.084). The variability explained through the variability between groups was significant and high  $I^2 = 99.38\%$  (Q = 13,950.7, df = 89, p < .001). When the research groups were restricted to those with known surface roughness and inclusion or exclusion of smokers  $t^2 = 0.56$  (SE = 0.093) was significant and the variability between groups remains high  $I^2 = 99.36\%$  (Q = 11,272.9, df = 76, p < .0001). The roughness of the surface was significant as mediating factor




Figure 3 Continued

(QM = 7.43, df = 2, p = .024). The residual heterogeneity remained significant  $t^2 = 0.5187$  (SE = 0.0878) and the variability between groups high  $I^2 = 99.27\%$  (Q = 10.956.63, df = 74, p < .0001). The mediator roughness introduced a reduction in residual homogeneity of 0.09%. The inclusion of smokers in the study did not lead to a significant decrease in heterogeneity. Note that the inclusion of smokers does not mean that a research group solely consisted of smokers and that the amount of smoking was not taken into account because was seldom reported objectively.

*Meta-Analysis.* For studies testing differences in surface roughness using one implant design the heterogeneity  $I^2$  between the studies was not significant (Q=0.45, df=2, p=.8001). The fixed effect model showed a significant difference in mean bone loss between minimally rough and moderately rough implant surfaces (Figure 4) with less bone loss for the former (z=3.1716, p=.0015).

Heterogeneity  $I^2 = 88.5\%$  for the studies evaluating the influence of periodontal history was significant equal to and the  $t^2$  medium (66.6%) (Q = 32.55,

df = 2, p = .0002). The random effects model showed a significant difference in mean bone loss between patient groups with a periodontal history and without a periodontal history (z = 2.1793, p = .029) (Figure 5). When only the rough surfaces were maintained the heterogeneity I<sup>2</sup> was no longer significant (Q = 1.76, df = 1, p = .1849). The random fixed effect model showed a significant difference with higher mean bone loss in patient groups with a periodontal history compared to periodontally healthy patients (z = 3.1822, p = .0015) (Figures 5 and 6).

Heterogeneity  $I^2 = 90.8$  of the studies comparing smoking and non-smoking with respect to bone loss was significant (Q = 32.55, df = 3, p < .0001) and  $t^2$  high (70.4%). The random effects model showed a significant difference in mean bone loss between smokers and non-smokers (z = 2.3008, p = .0214) (Figure 7).

## **DISCUSSION**

This paper scrutinized the literature on peri-implant bone loss in relation to implant surface roughness.

TABLE 5 Summary of Implant Survival % and Mean Bone Loss (expressed as positive value in mm), Standard Deviation and Standard Error for Each survival % Implant 96.4 98.4 Surface Roughness and Corresponding Proportion of Implants Estimated to lose bone >1 mm, >2 mm and >3 mm. t-Test was used for Statistica >3mm Proportion % implants 2 2 bone loss 20 18 51 51 p<00000 0<0.00001 p = 0.0002p<0.00001 Comparison with p ≤ 0.05 Being Statistically Significant p = 0.281.01 [0.98-1.04; 0.87; 0.0148] .04 [1.00-1.08; 1.01; 0.0189] [0.81-0.90; 0.84; 0.0212] .01 [1.00–1.03; 0.89; 0.0092 1.15 [1.11–1.19; 0.81; 0.021] Mean bone loss (mm) SD; SE 95% CI; 98.0 Surface roughness Moderately rough Unknown surface Minimally rough All studies Rough

The main focus was on bone loss for two reasons. First, ongoing bone loss is a prerequisite in the diagnosis of peri-implantitis and second, stability of peri-implant bone is considered a crucial determinant for implant success.

Because the process of bone level changes due to disease may take some years before being diagnosed clinically, 199 a minimal 5 year follow-up was set as inclusion criterion. Furthermore, since most of the surface modified implants have been launched commercially at the time of the millennium change and the scientific community has started to show serious interest in the peri-implantitis issue after some consensus meetings dating back to 2006<sup>200</sup> and onwards, <sup>40–43</sup> the authors decided to limit the search to papers published over the last 6 years to increase the likelihood of finding relevant papers. This also seems logical because some extra time passes before clinical research is reported and published in scientific journals. It is important to recall that the studies selected in this review reflect daily reality and are not limited to strictly selected patient groups. It may be an advantage that the inclusion was kept as broad as possible to ensure that all types of clinical studies were included. Conversely, this approach may also yield criticism and voice opposition based on how the literature was chosen. It may also account for the heterogeneity of the studies.

During data analysis we struggled especially with the time point of the first radiographic assessment of the bone level, used as baseline for bone loss comparisons. Indeed, it is well known that peri-implant bone loss may be affected by the time point considered as baseline for the evaluation. There is consensus that a radiograph should at least be taken at the time of loading to register the bone level as baseline for future comparison to ensure that bone loss can be calculated. 43 Often this delayed assessment approach leads to an underestimation of the total bone loss because initial crestal bone remodeling is not included.<sup>201</sup> Different authors described initial crestal bone loss as a consequence of biologic width reestablishment after implant placement in patients with thin soft tissues. 19,202 Another effect on the crestal bone loss could be the microcap between the implant and abutment in 2 piece implants.<sup>203,204</sup> This crestal bone loss is not only caused by the size and location of the microgap but also by the movement of the implant components. 14,205

E	xperim	ental		Co	ntrol	Mean difference				
Total	Mean	SD	Total	Mean	SD	20 2	MD	95%-CI	W(fixed)	W(random)
52	1.26	1.08	66	0.84	1.14	*	- 0.42	[ 0.02; 0.82]	20.9% 15.3% 63.8%	20.9% 15.3% 63.8%
		5822	275						100% 	100%
	Total 52 154 327	Total Mean b 121 1.73 52 1.26 154 2.00 327	Total Mean SD b 121 1.73 1.54 52 1.26 1.08 154 2.00 0.90	b 121 1.73 1.54 76 52 1.26 1.08 66 154 2.00 0.90 133 327 275	Total Mean SD Total Mean b 121 1.73 1.54 76 1.41 52 1.26 1.08 66 0.84 154 2.00 0.90 133 1.80 327 275	Total Mean         SD         Total Mean         SD           b         121         1.73         1.54         76         1.41         0.92           52         1.26         1.08         66         0.84         1.14           154         2.00         0.90         133         1.80         0.80           327         275	Total Mean SD Total Mean SD  50 121 1.73 1.54 76 1.41 0.92  52 1.26 1.08 66 0.84 1.14  154 2.00 0.90 133 1.80 0.80  327 275  equared=0, p=0.5822	Total Mean SD Total Mean SD MD  10 121 1.73 1.54 76 1.41 0.92 52 1.26 1.08 66 0.84 1.14 154 2.00 0.90 133 1.80 0.80  327 275  129 0.26  120 0.26  120 0.26	Total Mean SD Total Mean SD MD 95%-CI  b 121 1.73 1.54 76 1.41 0.92 52 1.26 1.08 66 0.84 1.14 154 2.00 0.90 133 1.80 0.80  327 275  quared=0, p=0.5822  MD 95%-CI  0.32 [-0.02; 0.66] 0.42 [0.02; 0.82] 0.20 [0.00; 0.40]	Total Mean SD Total Mean SD MD 95%-CI W(fixed)  b 121 1.73 1.54 76 1.41 0.92 52 1.26 1.08 66 0.84 1.14 154 2.00 0.90 133 1.80 0.80  327 275  0.26 [0.10; 0.42] 100% 0.26 [0.10; 0.42]

Figure 4 Forest plot for additional bone loss (expressed as positive value in mm) and moderately rough implant surfaces (experimental group) and minimally rough (control group).

Bacterial colonization of the exposed implant surface<sup>206–208</sup> may increase the risk for peri-implantitis. Vervaeke and colleagues<sup>133</sup> showed ongoing bone loss up to 9 years of function around implants with early bone loss in patients with other risk factors such as smoking and history of periodontitis. 133 Vandeweghe and colleagues<sup>209</sup> demonstrated that initial bone remodeling around immediately loaded implants occurs during the first 3 months in conjunction with biologic width establishment. Also with a one-stage surgery and delayed loading the soft tissue and bone healing starts at time of implant placement, yet this is not monitored when the baseline is taken at placement of the restoration several months later. For this review, however, we accepted the bone loss calculations based on a baseline at any given time point between implant installation and the first year. Additionally, it was impossible to control many other factors that may affect bone loss such as implant design, surgical technique, expertise level, prosthetic treatment protocols.<sup>210</sup> And last but not least, not all studies have the same follow-up time nor comparable patients' profiles with respect to risk factors such as smoking habits or periodontal history. It is our belief, however, that this flaw affects all studies irrespective of implant system or implant surface roughness and hence is of secondary importance in the context of the comparison of various surface roughness and its effect on bone loss.

One of the observations of the review was that very few papers actually report on peri-implantitis prevalence and those that do so often use different diagnostic thresholds or have incomplete data reporting and missing parameters. Only 6 papers of the 87 quoted all diagnostic parameters, suggested as essential to diagnose peri-implantitis.43 This reflects that some studies yield extremely high "self-quoted" prevalence of peri-implantitis despite extremely low mean bone loss values, 140,163 which is indicative of low bone loss thresholds, whereas others have extremely low prevalence percentage despite contradictory high bone loss values. 163,189 These findings question the reliability of those self-reported prevalences, especially when incomplete data are presented, and point to the necessity of using more straightforward and objective parameters, such as bone loss over time. It can be concluded that researchers deliberately pay less attention to the assessment of parameters to diagnose peri-implantitis and that there is still no consensus on the criteria to define peri-implantitis.

By and large, the mean weighted bone loss ranged between 0 and 2 mm in 90% of the study groups (Figure 3, A–C). Only in 9/123 study groups (7.3%) was the mean bone loss above 2 mm as reported in 3 studies. However, since mean values may hide the real problematic cases, the statistical analysis using mean value and standard deviation





Figure 5 Forest plot for additional bone loss (expressed as positive value in mm) between patient groups with a periodontal history (experimental group) and without a periodontal history (control group) including one study using implants with a minimally rough surface and two studies using a rough surface.



**Figure 6** Forest plot for additional bone loss (expressed as positive value in mm) between patient groups with a periodontal history (experimental group) and without a periodontal history (control group) reduced to the two studies using implants with a rough surface.

allowed calculation of number of implants with an arbitrarily chosen bone loss threshold of above 1, 2, or 3 mm. We adopted the 2 mm bone loss threshold as proposed by Klinge and colleagues<sup>211</sup> since this could be suggestive of "risk-zone" cases.

The overall results demonstrate that 49% and 18% of all implants in the 87 studies lost more than 1 mm and 2 mm bone, respectively, during function above 5 years. It seems logical to conclude that setting a threshold for disease below this value is unrealistic and probably leads to false positive diagnosis of disease. Only 5% of the implants lost more than 3 mm bone. The proportion of implants losing above 2 mm bone is 14%, 18%, and 20% for minimally rough, moderately rough, and rough surfaces, respectively. Of course, the prevalence of 2 or 3 mm bone loss does not necessarily equals peri-implantitis. The approach applied in our paper may even overestimate the prevalence of peri-implantitis because bone loss should be accompanied by inflammation of the surrounding tissues as demonstrated by the presence of bleeding or pus. This explains why self-reported periimplantitis prevalence (Table 4) does not always correspond with the prevalence of bone loss above 2 to 3 mm as reported in Table 3. The paper of Roccuzzo<sup>198</sup> demonstrates nicely that implants placed in patients with aggressive periodontal disease history have 15.1% peri-implantitis but only 1% of bone loss

above 2 or 3. Meyle and colleagues<sup>140</sup> has no implants with bone loss above 2 mm yet finds 24% of perimplantitis due to 27% bleeding. This seems suggestive of mucositis diagnosis instead of peri-implantitis. The parameters bleeding or the bone loss threshold taken for disease seem to have a very decisive effect in rocketing peri-implantitis upwards in many studies. Interestingly, in an 18-year follow-up study, Dierens and colleagues<sup>212</sup> demonstrated that bleeding on probing is a bad predictor for bone loss or peri-implantitis.

There is a statistically significant difference in the mean bone loss calculated between the various roughness groups with a trend for higher bone loss for the rougher implant surface (Table 5). Whether this is of clinical significance remains disputable taking heterogeneity of the studies into account. Furthermore, one should take into consideration a 0.3 to 0.5 mm measurement error when performing radiographic bone assessments.

Hence, a better approach is to compare implants with equal design but only differing in surface topography in prospective randomized controlled trials. Unfortunately, the only available prospective trial was excluded because of missing standard deviation, required to do the statistics. The other three studies, albeit of retrospective design, were testing minimally rough surfaces and moderately rough surfaces with




Figure 7 Forest plot for additional bone loss (expressed as positive value in mm) between smokers (experimental group) and non-smokers (control group).

similar implant designs. Hence, these three studies were apt for meta-analysis as shown in Figure 4. The minimally rough surface was statistically better in minimizing bone loss. However, the amount of studies is scarce and more research is required to confirm this finding.

#### **CONCLUSIONS**

Although rough surface implants induce statistically significant more bone loss according to the present meta-analysis, the clinical impact of surface roughness on bone loss is limited in the majority of the papers. The multifactorial cause for bone loss and the heterogeneity of the studies, related to inclusion of risk patients as well as poor data reporting, make it difficult to draw strong conclusions regarding the effect of implant surface roughness on bone loss over time. Nevertheless, independent of surface or implant brand, bone loss above 3 mm occurs in less than 5% of all implants after at least 5 years in function. Moreover, the meta-analysis indicates that co-factors such as smoking or periodontal disease increase the risk for bone loss.

#### **REFERENCES**

- 1. ten Bruggenkate CM, van der Kwast WA, Oosterbeek HS. Success criteria in oral implantology. A review of the literature. Int J Oral Implantol 1990; 7:45–51.
- 2. Albrektsson T, Zarb G, Worthington P, Eriksson AR. The long-term efficacy of currently used dental implants: a review and proposed criteria of success. Int J Oral Maxillofac Implants 1986; 1:11–25.
- Misch CE, Perel ML, Wang HL, et al. Implant success, survival, and failure: the International Congress of Oral Implantologists (ICOI) Pisa Consensus Conference. Implant Dent 2008; 17:5–15.
- Collaert B, De Bruyn H. Immediate functional loading of TiOblast dental implants in full-arch edentulous maxillae: a 3-year prospective study. Clin Oral Implants Res 2008; 19:1254–1260.
- 5. Klinge B. Peri-implant marginal bone loss: an academic controversy or a clinical challenge? Eur J Oral Implantol 2012; 5 Suppl:S13–S19.
- Albrektsson T, Branemark PI, Hansson HA, Lindstrom J. Osseointegrated titanium implants. Requirements for ensuring a long-lasting, direct bone-to-implant anchorage in man. Acta Orthop Scand 1981; 52:155–170.
- 7. Adell R, Lekholm U, Rockler B, Branemark PI. A 15-year study of osseointegrated implants in the treatment of the edentulous jaw. Int J Oral Surg 1981; 10:387–416.

- 8. Ekelund JA, Lindquist LW, Carlsson GE, Jemt T. Implant treatment in the edentulous mandible: a prospective study on Branemark system implants over more than 20 years. Int J Prosthodont 2003; 16:602–608.
- Jemt T, Johansson J. Implant treatment in the edentulous maxillae: a 15-year follow-up study on 76 consecutive patients provided with fixed prostheses. Clin Implant Dent Relat Res 2006; 8:61–69.
- Lekholm U, Grondahl K, Jemt T. Outcome of oral implant treatment in partially edentulous jaws followed 20 years in clinical function. Clin Implant Dent Relat Res 2006; 8:178–186.
- Gotfredsen K, Karlsson U. A prospective 5-year study of fixed partial prostheses supported by implants with machined and TiO2-blasted surface. J Prosthodont 2001; 10:2–7.
- 12. Buser D, Mericske-Stern R, Bernard JP, et al. Long-term evaluation of non-submerged ITI implants. Part 1: 8-year life table analysis of a prospective multi-center study with 2359 implants. Clin Oral Implants Res 1997; 8:161–172.
- 13. Esposito M, Hirsch JM, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (II). Etiopathogenesis. Eur J Oral Sci 1998; 106:721–764.
- 14. Hermann JS, Cochran DL, Nummikoski PV, Buser D. Crestal bone changes around titanium implants. A radiographic evaluation of unloaded nonsubmerged and submerged implants in the canine mandible. J Periodontol 1997; 68:1117–1130.
- 15. Raes F, Cosyn J, Crommelinck E, Coessens P, De Bruyn H. Immediate and conventional single implant treatment in the anterior maxilla: 1-year results of a case series on hard and soft tissue response and aesthetics. J Clin Periodontol 2011; 38:385–394.
- Heitz-Mayfield LJ, Lang NP. Comparative biology of chronic and aggressive periodontitis vs. peri-implantitis. Periodontol 2000 2010; 53:167–181.
- 17. Lindhe J, Meyle J. Peri-implant diseases: consensus report of the sixth European workshop on periodontology. J Clin Periodontol 2008; 35(8 Suppl):282–285.
- 18. Linkevicius T, Apse P, Grybauskas S, Puisys A. The influence of soft tissue thickness on crestal bone changes around implants: a 1-year prospective controlled clinical trial. Int J Oral Maxillofac Implants 2009; 24:712–719.
- 19. Vervaeke S, Dierens M, Besseler J, De Bruyn H. The influence of initial soft tissue thickness on peri-implant bone remodeling. Clin Implant Dent Relat Res 2014; 16: 238–247.
- Galindo-Moreno P, Leon-Cano A, Ortega-Oller I, et al. Prosthetic abutment height is a key factor in periimplant marginal bone loss. J Dent Res 2014; 93(7 Suppl):80S–85S.

- Norderyd O, Hugoson A, Grusovin G. Risk of severe periodontal disease in a Swedish adult population. A longitudinal study. J Clin Periodontol 1999; 26:608–615.
- 22. Schatzle M, Loe H, Lang NP, Burgin W, Anerud A, Boysen H. The clinical course of chronic periodontitis. J Clin Periodontol 2004; 31:1122–1127.
- 23. Ferreira SD, Silva GL, Cortelli JR, Costa JE, Costa FO. Prevalence and risk variables for peri-implant disease in Brazilian subjects. J Clin Periodontol 2006; 33:929–935.
- 24. Roccuzzo M, De AN, Bonino L, Aglietta M. Ten-year results of a three-arm prospective cohort study on implants in periodontally compromised patients. Part 1: implant loss and radiographic bone loss. Clin Oral Implants Res 2010; 21:490–496.
- 25. van der Weijden GA, van Bemmel KM, Renvert S. Implant therapy in partially edentulous, periodontally compromised patients: a review. J Clin Periodontol 2005; 32:506–511.
- 26. Karoussis IK, Kotsovilis S, Fourmousis I. A comprehensive and critical review of dental implant prognosis in periodontally compromised partially edentulous patients. Clin Oral Implants Res 2007; 18:669–679.
- Klokkevold PR, Han TJ. How do smoking, diabetes, and periodontitis affect outcomes of implant treatment? Int J Oral Maxillofac Implants 2007; 22 Suppl:173–202.
- Quirynen M, Abarca M, Van AN, Nevins M, van SD. Impact of supportive periodontal therapy and implant surface roughness on implant outcome in patients with a history of periodontitis. J Clin Periodontol 2007; 34: 805–815.
- 29. Al-Zahrani MS. Implant therapy in aggressive periodontitis patients: a systematic review and clinical implications. Quintessence Int 2008; 39:211–215.
- Ong CT, Ivanovski S, Needleman IG, et al. Systematic review of implant outcomes in treated periodontitis subjects. J Clin Periodontol 2008; 35:438–462.
- 31. Schou S. Implant treatment in periodontitis-susceptible patients: a systematic review. J Oral Rehabil 2008; 35 Suppl 1:9–22.
- Renvert S, Persson GR. Periodontitis as a potential risk factor for peri-implantitis. J Clin Periodontol 2009; 36 Suppl 10:9–14.
- 33. Faggion CM, Jr, Giannakopoulos NN. Critical appraisal of systematic reviews on the effect of a history of periodontitis on dental implant loss. J Clin Periodontol 2013; 40:542–552.
- Palmer RM, Wilson RF, Hasan AS, Scott DA. Mechanisms of action of environmental factors–tobacco smoking. J Clin Periodontol 2005; 32 Suppl 6:180–195.
- 35. Hinode D, Tanabe S, Yokoyama M, Fujisawa K, Yamauchi E, Miyamoto Y. Influence of smoking on osseointegrated implant failure: a meta-analysis. Clin Oral Implants Res 2006; 17:473–478.

- Strietzel FP, Reichart PA, Kale A, Kulkarni M, Wegner B, Kuchler I. Smoking interferes with the prognosis of dental implant treatment: a systematic review and metaanalysis. J Clin Periodontol 2007; 34:523–544.
- 37. Lindquist LW, Carlsson GE, Jemt T. A prospective 15-year follow-up study of mandibular fixed prostheses supported by osseointegrated implants. Clinical results and marginal bone loss. Clin Oral Implants Res 1996; 7:329–336.
- Teughels W, Van AN, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Implants Res 2006; 17 Suppl 2:68–81.
- 39. Chappuis V, Buser R, Bragger U, Bornstein MM, Salvi GE, Buser D. Long-term outcomes of dental implants with a titanium plasma-sprayed surface: a 20-year prospective case series study in partially edentulous patients. Clin Implant Dent Relat Res 2013; 15:780–790.
- Hammerle CH, Quirynen M. The second EAO consensus conference 19-22 February 2009, Pfaffikon, Switzerland. Preface. Clin Oral Implants Res 2009; 20 Suppl 4:1.
- Tonetti M, Palmer R. Clinical research in implant dentistry: study design, reporting and outcome measurements: consensus report of Working Group 2 of the VIII European Workshop on Periodontology. J Clin Periodontol 2012;39 Suppl 12:73–80.
- 42. Klinge B, van SD. Working group on treatment options for the maintenance of marginal bone around endosseous oral implants, Stockholm, Sweden, 8 and 9 September 2011. Methodology. Eur J Oral Implantol 2012; 5 Suppl:S9–12.
- 43. Sanz M, Chapple IL. Clinical research on peri-implant diseases: consensus report of Working Group 4. J Clin Periodontol 2012; 39 Suppl 12:202–206.
- 44. Kan JY, Rungcharassaeng K, Lozada JL, Zimmerman G. Facial gingival tissue stability following immediate placement and provisionalization of maxillary anterior single implants: a 2- to 8-year follow-up. Int J Oral Maxillofac Implants 2011; 26:179–187.
- 45. Lopez-Piriz R, Morales A, Gimenez MJ, et al. Correlation between clinical parameters characterising perimplant and periodontal health: a practice-based research in Spain in a series of patients with implants installed 4-5 years ago. Med Oral Patol Oral Cir Bucal 2012; 17:e893–e901.
- 46. Soardi CM, Zandanel E, Rebuffini E, Carinci R. A retrospective study on a series of 556 zimmer dental implants. Dent Res J (Isfahan) 2012; 9(Suppl 2):S181–S185.
- 47. Paul S, Held U. Immediate supracrestal implant placement with immediate temporization in the anterior dentition: a retrospective study of 31 implants in 26 patients with up to 5.5-years follow-up. Clin Oral Implants Res 2013; 24:710–717.

- 48. Dagorne C, Malet J, Bizouard G, Mora F, Range H, Bouchard P. Clinical evaluation of two dental implant macrostructures on peri-implant bone loss: a comparative, retrospective study. Clin Oral Implants Res 2015; 26:307–313.
- 49. Ata-Ali J, Flichy-Fernandez AJ, Alegre-Domingo T, Ata-Ali F, Palacio J, Penarrocha-Diago M. Clinical, microbiological, and immunological aspects of healthy versus peri-implantitis tissue in full arch reconstruction patients: a prospective cross-sectional study. BMC Oral Health 2015; 15:43.
- Jervoe-Storm PM, Jepsen S, Johren P, Mericske-Stern R, Enkling N. Internal bacterial colonization of implants: association with peri-implant bone loss. Clin Oral Implants Res 2015; 26:957–963.
- Zafiropoulos GG, Deli G, Vittorini G, Hoffmann O. Implant placement and immediate loading with fixed restorations in augmented sockets. Five-year results. A case report. J Oral Implantol 2013; 39:372–379.
- 52. Romanos GE, Gaertner K, Aydin E, Nentwig GH. Longterm results after immediate loading of platformswitched implants in smokers versus nonsmokers with full-arch restorations. Int J Oral Maxillofac Implants 2013; 28:841–845.
- 53. Vanlioglu BA, Ozkan Y, Evren B, Ozkan YK. Experimental custom-made zirconia abutments for narrow implants in esthetically demanding regions: a 5-year follow-up. Int J Oral Maxillofac Implants 2012; 27:1239–1242.
- 54. Bahat O, Sullivan RM, Smidt A. Placement of Branemark Mk IV implants in compromised and grafted bone: radiographic outcome of 61 sites in 27 patients with 3- to 7-year follow-ups. Quintessence Int 2012; 43: 293–303.
- 55. Romeo E, Storelli S, Casano G, Scanferla M, Botticelli D. Six-mm versus 10-mm long implants in the rehabilitation of posterior edentulous jaws: a 5-year follow-up of a randomised controlled trial. Eur J Oral Implantol 2014; 7:371–381.
- 56. Cortellini P, Stalpers G, Mollo A, Tonetti MS. Periodontal regeneration versus extraction and prosthetic replacement of teeth severely compromised by attachment loss to the apex: 5-year results of an ongoing randomized clinical trial. J Clin Periodontol 2011; 38:915–924.
- 57. Ozkan Y, Akoglu B, Kulak-Ozkan Y. Maxillary sinus floor augmentation using bovine bone grafts with simultaneous implant placement: a 5-year prospective follow-up study. Implant Dent 2011; 20:455–459.
- 58. Ozkan Y, Akoglu B, Kulak-Ozkan Y. Five-year treatment outcomes with four types of implants in the posterior maxilla and mandible in partially edentulous patients: a retrospective study. Int J Oral Maxillofac Implants 2011; 26:639–647.
- 59. Akoglu B, Ucankale M, Ozkan Y, Kulak-Ozkan Y. Fiveyear treatment outcomes with three brands of implants

- supporting mandibular overdentures. Int J Oral Maxillofac Implants 2011; 26:188–194.
- 60. Stacchi C, Chen ST, Raghoebar GM, et al. Malpositioned osseointegrated implants relocated with segmental osteotomies: a retrospective analysis of a multicenter case series with a 1- to 15-year follow-up. Clin Implant Dent Relat Res 2013; 15:836–846.
- 61. Malo P, de Araujo NM, Borges J, Almeida R. Retrievable metal ceramic implant-supported fixed prostheses with milled titanium frameworks and all-ceramic crowns: retrospective clinical study with up to 10 years of follow-up. J Prosthodont 2012; 21:256–264.
- 62. Fugazzotto P. A retrospective analysis of immediately placed implants in 418 sites exhibiting periapical pathology: results and clinical considerations. Int J Oral Maxillofac Implants 2012; 27:194–202.
- 63. Swierkot K, Lottholz P, Flores-de-Jacoby L, Mengel R. Mucositis, peri-implantitis, implant success, and survival of implants in patients with treated generalized aggressive periodontitis: 3- to 16-year results of a prospective long-term cohort study. J Periodontol 2012; 83:1213–1225.
- 64. Degidi M, Nardi D, Daprile G, Piattelli A. Buccal bone plate in the immediately placed and restored maxillary single implant: a 7-year retrospective study using computed tomography. Implant Dent 2012; 21:62–66.
- 65. Ormianer Z, Patel A. The use of tapered implants in the maxillae of periodontally susceptible patients: 10-year outcomes. Int J Oral Maxillofac Implants 2012; 27:442–448.
- 66. Rocci A, Rocci M, Scoccia A, Martignoni M, Gottlow J, Sennerby L. Immediate loading of maxillary prostheses using flapless surgery, implant placement in predetermined positions, and prefabricated provisional restorations. Part 2: a retrospective 10-year clinical study. Int J Oral Maxillofac Implants 2012; 27:1199–1204.
- 67. Covani U, Chiappe G, Bosco M, Orlando B, Quaranta A, Barone A. A 10-year evaluation of implants placed in fresh extraction sockets: a prospective cohort study. J Periodontol 2012; 83:1226–1234.
- 68. Wilson TG, Jr., Roccuzzo M, Ucer C, Beagle JR. Immediate placement of tapered effect (TE) implants: 5-year results of a prospective, multicenter study. Int J Oral Maxillofac Implants 2013; 28:261–269.
- 69. Harel N, Piek D, Livne S, Palti A, Ormianer Z. A 10-year retrospective clinical evaluation of immediately loaded tapered maxillary implants. Int J Prosthodont 2013; 26:244–249.
- Romanos GE, Gaertner K, Nentwig GH. Long-term evaluation of immediately loaded implants in the edentulous mandible using fixed bridges and platform shifting. Clin Implant Dent Relat Res 2014; 16:601–608.
- 71. Harel N, Moses O, Palti A, Ormianer Z. Long-term results of implants immediately placed into extraction

- sockets grafted with beta-tricalcium phosphate: a retrospective study. J Oral Maxillofac Surg 2013; 71: e63–e68.
- Canullo L, Penarrocha-Oltra D, Covani U, Botticelli D, Serino G, Penarrocha M. Clinical and microbiological findings in patients with peri-implantitis: a crosssectional study. Clin Oral Implants Res 2016; 27: 376–382.
- 73. Felice P, Cannizzaro G, Barausse C, Pistilli R, Esposito M. Short implants versus longer implants in vertically augmented posterior mandibles: a randomised controlled trial with 5-year after loading follow-up. Eur J Oral Implantol 2014; 7:359–369.
- 74. Frisch E, Ratka-Kruger P, Wenz HJ. Unsplinted implants and teeth supporting maxillary removable partial dentures retained by telescopic crowns: a retrospective study with >6 years of follow-up. Clin Oral Implants Res 2015; 26:1091–1097.
- 75. Woelber JP, Ratka-Krueger P, Vach K, Frisch E. Decementation rates and the peri-implant tissue status of implant-supported fixed restorations retained via zinc oxide cement: a retrospective 10-23-year study. Implant Dent Relat Res 2016; 18:917–925.
- 76. Malo P, de Araujo NM, Lopes A, Ferro A, Gravito I. Single-tooth rehabilitations supported by dental implants used in an immediate-provisionalization protocol: report on long-term outcome with retrospective follow-up. Clin Implant Dent Relat Res 2015; 17 Suppl 2:e511–e519.
- Trullenque-Eriksson A, Guisado MB. Retrospective longterm evaluation of dental implants in totally and partially edentulous patients: part II: periimplant disease. Implant Dent 2015; 24:217–221.
- 78. Jemt T, Sunden PS, Grondahl K. Changes of marginal bone level in patients with "Progressive Bone Loss" at Branemark System(R) Implants: a radiographic follow-up study over an average of 9 years. Clin Implant Dent Relat Res 2015; 17:619–628.
- 79. Melo AC, Toscano R, Vieira RA, Sartori IA, Bernardes SR, Thome G. Immediate loading of edentulous mandible with prefabricated bars: a long-term study of 7 years. Implant Dent 2015; 24:472–476.
- 80. Yaltirik M, Gokcen-Rohlig B, Ozer S, Evlioglu G. Clinical evaluation of small diameter straumann implants in partially edentulous patients: a 5-year retrospective study. J Dent (Tehran) 2011; 8:75–80.
- 81. Ueda T, Kremer U, Katsoulis J, Mericske-Stern R. Long-term results of mandibular implants supporting an overdenture: implant survival, failures, and crestal bone level changes. Int J Oral Maxillofac Implants 2011; 26:365–372.
- 82. Stoker G, van WR, Wismeijer D. Long-term outcomes of three types of implant-supported mandibular overdentures in smokers. Clin Oral Implants Res 2012; 23: 925–929.

- 83. Krennmair G, Seemann R, Weinlander M, Piehslinger E. Comparison of ball and telescopic crown attachments in implant-retained mandibular overdentures: a 5-year prospective study. Int J Oral Maxillofac Implants 2011; 26: 598–606.
- 84. Oliva J, Oliva X, Oliva JD. All-on-three delayed implant loading concept for the completely edentulous maxilla and mandible: a retrospective 5-year follow-up study. Int J Oral Maxillofac Implants 2012; 27:1584–1592.
- 85. Moeintaghavi A, Radvar M, Arab HR, Boostani HR, Ghiami E. Evaluation of 3- to 8-year treatment outcomes and success rates with 6 implant brands in partially edentulous patients. J Oral Implantol 2012; 38 Spec No:441–448.
- 86. Pettersson P, Sennerby L. A 5-year retrospective study on Replace Select Tapered dental implants. Clin Implant Dent Relat Res 2015; 17:286–295.
- 87. Sivolella S, Stellini E, Testori T, Di FA, Berengo M, Lops D. Splinted and unsplinted short implants in mandibles: a retrospective evaluation with 5 to 16 years of follow-up. J Periodontol 2013; 84:502–512.
- 88. Berberi AN, Sabbagh JM, Aboushelib MN, Noujeim ZF, Salameh ZA. A 5-year comparison of marginal bone level following immediate loading of single-tooth implants placed in healed alveolar ridges and extraction sockets in the maxilla. Front Physiol 2014; 5:29.
- 89. Mangano F, Shibli JA, Sammons RL, Veronesi G, Piattelli A, Mangano C. Clinical outcome of narrow-diameter (3.3-mm) locking-taper implants: a prospective study with 1 to 10 years of follow-up. Int J Oral Maxillofac Implants 2014; 29:448–455.
- Rossi F, Lang NP, Ricci E, Ferraioli L, Marchetti C, Botticelli D. Early loading of 6-mm-short implants with a moderately rough surface supporting single crowns—a prospective 5-year cohort study. Clin Oral Implants Res 2015; 26:471–477.
- 91. Vazquez AR, Perez SM, Gayoso DP, Garcia GA. Factors affecting peri-implant bone loss: a post-five-year retrospective study. Clin Oral Implants Res 2015; 26:1006–1014.
- Nack C, Raguse JD, Stricker A, Nelson K, Nahles S. Rehabilitation of irradiated patients with chemically modified and conventional SLA implants: five-year follow-up. J Oral Rehabil 2015; 42:57–64.
- 93. Korfage A, Raghoebar GM, Slater JJ, et al. Overdentures on primary mandibular implants in patients with oral cancer: a follow-up study over 14 years. Br J Oral Maxillofac Surg 2014; 52:798–805.
- 94. Cavalli N, Corbella S, Taschieri S, Francetti L. Prevalence of peri-implant mucositis and peri-implantitis in patients treated with a combination of axial and tilted implants supporting a complete fixed denture. Sci World J 2015; 2015;874842.

- 95. Malo P, Nobre MA, Lopes A, Ferro A, Gravito I. Immediate loading of implants placed in patients with untreated periodontal disease: a 5-year prospective cohort study. Eur J Oral Implantol 2014; 7:295–304.
- 96. Anitua E, Saracho J, Begona L, Alkhraisat MH. Long-term follow-up of 2.5-mm narrow-diameter implants supporting a fixed prostheses. Clin Implant Dent Relat Res 2016; 18:769–777.
- 97. Ebinger A, Katsoulis J, Hakimi M, Mazzi D, Mericske-Stern R. Mucosal manifestations in the edentulous maxilla with implant supported prostheses: clinical results from a well-maintained patient cohort. Clin Implant Dent Relat Res 2016; 18:639–648.
- 98. Jeong MA, Jung MK, Kim SG, Oh JS. Implant stability measurements in the long-term follow-up of dentis implants: a retrospective study with periotest. Implant Dent 2015; 24:263–266.
- 99. Konstantinidis IK, Kotsakis GA, Gerdes S, Walter MH. Cross-sectional study on the prevalence and risk indicators of peri-implant diseases. Eur J Oral Implantol 2015; 8:75–88.
- 100. Fretwurst T, Nack C, Al-Ghrairi M, et al. Long-term retrospective evaluation of the peri-implant bone level in onlay grafted patients with iliac bone from the anterior superior iliac crest. J Craniomaxillofac Surg 2015; 43: 956–960.
- 101. Krebs M, Schmenger K, Neumann K, Weigl P, Moser W, Nentwig GH. Long-term evaluation of ANKYLOS(R) dental implants, part i: 20-year life table analysis of a longitudinal study of more than 12,500 implants. Clin Implant Dent Relat Res 2015; 17 Suppl 1:e275–e286.
- 102. Quaranta A, Assenza B, D'isidoro O, Profili F, Polimeni A, Vozza I. The impact of smoking and previous periodontal disease on peri-implant microbiota and health: a retrospective study up to 7-year follow-up. Ann Stomatol (Roma) 2015; 6:21–28.
- 103. Rossi F, Botticelli D, Cesaretti G, De SE, Storelli S, Lang NP. Use of short implants (6 mm) in a single-tooth replacement: a 5-year follow-up prospective randomized controlled multicenter clinical study. Clin Oral Implants Res 2016; 27:458–464.
- 104. Mijiritsky E, Lorean A, Mazor Z, Levin L. Implant tooth-supported removable partial denture with at least 15-year long-term follow-up. Clin Implant Dent Relat Res 2015; 17:917–922.
- 105. Grassi FR, Capogreco M, Consonni D, Bilardi G, Buti J, Kalemaj Z. Immediate occlusal loading of one-piece zirconia implants: five-year radiographic and clinical evaluation. Int J Oral Maxillofac Implants 2015; 30:671–680.
- 106. Dasmah A, Thor A, Ekestubbe A, Sennerby L, Rasmusson L. Marginal bone-level alterations at implants installed in block versus particulate onlay bone grafts mixed with platelet-rich plasma in atrophic

- maxilla. a prospective 5-year follow-up study of 15 patients. Clin Implant Dent Relat Res 2013; 15:7–14.
- 107. De Bruyn H, Bouvry P, Collaert B, De CC, Persson GR, Cosyn J. Long-term clinical, microbiological, and radiographic outcomes of Branemark implants installed in augmented maxillary bone for fixed full-arch rehabilitation. Clin Implant Dent Relat Res 2013; 15:73–82.
- 108. Sbordone C, Toti P, Guidetti F, Califano L, Santoro A, Sbordone L. Volume changes of iliac crest autogenous bone grafts after vertical and horizontal alveolar ridge augmentation of atrophic maxillas and mandibles: a 6-year computerized tomographic follow-up. J Oral Maxillofac Surg 2012; 70:2559–2565.
- 109. Stellingsma K, Raghoebar GM, Visser A, Vissink A, Meijer HJ. The extremely resorbed mandible, 10-year results of a randomized controlled trial on 3 treatment strategies. Clin Oral Implants Res 2014; 25:926–932.
- Duttenhoefer F, Nack C, Doll C, et al. Long-term periimplant bone level changes of non-vascularized fibula bone grafted edentulous patients. J Craniomaxillofac Surg 2015; 43:611–615.
- 111. Zou D, Wang F, Wu Y, Huang W, Zhang C, Zhang Z. Implant-supported telescopic crown-retained overdentures for oral rehabilitation of patients with severe bony defects: a 5-year retrospective study. Int J Oral Maxillofac Implants 2015; 30:937–944.
- 112. Hjalmarsson L, Smedberg JI, Pettersson M, Jemt T. Implant-level prostheses in the edentulous maxilla: a comparison with conventional abutment-level prostheses after 5 years of use. Int J Prosthodont 2011; 24:158–167.
- 113. Becker W, Hujoel P, Becker BE, Wohrle P. Dental implants in an aged population: evaluation of periodontal health, bone loss, implant survival, and quality of life. Clin Implant Dent Relat Res 2016; 18:473–479.
- 114. Imburgia M, Del FM. Long-term retrospective clinical and radiographic follow-up of 205 Branemark System Mk III TiUnite implants submitted to either immediate or delayed loading. Implant Dent 2015; 24:533–540.
- 115. Hoeksema AR, Visser A, Raghoebar GM, Vissink A, Meijer HJ. Influence of age on clinical performance of mandibular two-implant overdentures: a 10-year prospective comparative study. Clin Implant Dent Relat Res 2016; 18:745–751.
- 116. Vandeweghe S, Hawker P,D, Bruyn H. An up to 12-year retrospective follow-up on immediately loaded, surface-modified implants in the edentulous mandible. Clin Implant Dent Relat Res 2016; 18:323–331.
- 117. Vandeweghe S, Ferreira D, Vermeersch L, Marien M,D, Bruyn H. Long-term retrospective follow-up of turned and moderately rough implants in the edentulous jaw. Clin Oral Implants Res 2016; 27:421–426.
- 118. Nedir R, Nurdin N, Vazquez L, Abi NS, Bischof M. Osteotome sinus floor elevation without grafting: a 10-

- year prospective study. Clin Implant Dent Relat Res 2016; 18:609–617.
- 119. Park W, Park Y, Park H, et al. A 10-year retrospective radiographic study of implantium dental implants. Int J Periodontics Restorative Dent 2015; 35:49–54.
- 120. Eerdekens L, Schols M, Coelst L, Quirynen M, Naert I. A 5-year prospective study on cone-anchored implants in the Edentulous Maxilla. Clin Implant Dent Relat Res 2015; 17 Suppl 2:e621–e632.
- 121. Perrotti V, Ravera L, Ricci L, et al. Radiographic comparison of periimplant bone resorption and assessment of survival rates of 2 implant systems: a 10-year prospective multicenter study. Implant Dent 2015; 24:77–82.
- 122. Romanos GE, Aydin E, Locher K, Nentwig GH. Immediate vs. delayed loading in the posterior mandible: a split-mouth study with up to 15 years of follow-up. Clin Oral Implants Res 2016; 27:e74–e79.
- 123. Zhao X, Qiao SC, Shi JY, Uemura N, Arai K, Lai HC. Evaluation of the clinical and aesthetic outcomes of Straumann((R)) Standard Plus implants supported single crowns placed in non-augmented healed sites in the anterior maxilla: a 5-8 years retrospective study. Clin Oral Implants Res 2016; 27:106–112.
- 124. Crespi R, Cappare P, Gastaldi G, Gherlone EF. Immediate occlusal loading of full-arch rehabilitations: screwretained versus cement-retained prosthesis. An 8-year clinical evaluation. Int J Oral Maxillofac Implants 2014; 29:1406–1411.
- 125. van Velzen FJ, Ofec R, Schulten EA, Ten Bruggenkate CM. 10-year survival rate and the incidence of perimplant disease of 374 titanium dental implants with a SLA surface: a prospective cohort study in 177 fully and partially edentulous patients. Clin Oral Implants Res 2015; 26:1121–1128.
- 126. Trullenque-Eriksson A, Guisado-Moya B. Retrospective long-term evaluation of dental implants in totally and partially edentulous patients. Part I: survival and marginal bone loss. Implant Dent 2014; 23:732–737.
- 127. Joda T, Michelaki I, Heydecke G. Peri-implant bone loss of dental implants with platform-switching design after 5 years of loading: a cross-sectional study. Quintessence Int 2015; 46:59–66.
- 128. Meijer HJ, Raghoebar GM, de Waal YC, Vissink A. Incidence of peri-implant mucositis and peri-implantitis in edentulous patients with an implant-retained mandibular overdenture during a 10-year follow-up period. J Clin Periodontol 2014; 41:1178–1183.
- 129. Slotte C, Gronningsaeter A, Halmoy AM, et al. Four-millimeter-long posterior-mandible implants: 5-year out-comes of a prospective multicenter study. Clin Implant Dent Relat Res 2015; 17 Suppl 2:e385–e395.
- 130. Schropp L, Wenzel A, Stavropoulos A. Early, delayed, or late single implant placement: 10-year results from a

- randomized controlled clinical trial. Clin Oral Implants Res 2014; 25:1359–1365.
- 131. Gholami H, Mericske-Stern R, Kessler-Liechti G, Katsoulis J. Radiographic bone level changes of implantsupported restorations in edentulous and partially dentate patients: 5-year results. Int J Oral Maxillofac Implants 2014; 29:898–904.
- 132. Cooper LF, Reside G, Raes F, et al. Immediate provisionalization of dental implants in grafted alveolar ridges in the esthetic zone: a 5-year evaluation. Int J Periodontics Restorative Dent 2014; 34:477–486.
- 133. Vervaeke S, Collaert B, Cosyn J, De Bruyn H. A 9-year prospective case series using multivariate analyses to identify predictors of early and late peri-implant bone loss. Clin Implant Dent Relat Res 2016; 18:30–39.
- 134. Mangano C, Iaculli F, Piattelli A, Mangano F. Fixed restorations supported by Morse-taper connection implants: a retrospective clinical study with 10-20 years of follow-up. Clin Oral Implants Res 2015; 26:1229–1236.
- 135. Simion M, Gionso L, Grossi GB, Briguglio F, Fontana F. Twelve-year retrospective follow-up of machined implants in the Posterior Maxilla: radiographic and perimplant outcome. Clin Implant Dent Relat Res 2015; 17 Suppl 2:e343–e351.
- 136. Tealdo T, Menini M, Bevilacqua M, et al. Immediate versus delayed loading of dental implants in edentulous patients' maxillae: a 6-year prospective study. Int J Prosthodont 2014; 27:207–214.
- 137. Covani U, Canullo L, Toti P, Alfonsi F, Barone A. Tissue stability of implants placed in fresh extraction sockets: a 5-year prospective single-cohort study. J Periodontol 2014; 85:e323–e332.
- 138. Cooper LF, Reside GJ, Raes F, et al. Immediate provisionalization of dental implants placed in healed alveolar ridges and extraction sockets: a 5-year prospective evaluation. Int J Oral Maxillofac Implants 2014; 29:709–717.
- 139. Leventi E, Malden NJ, Lopes VR. Periimplant bone-level reduction in relation to hydroxyapatite-coated dental implants that act as mandibular overdenture retainers: results at 6 to 10 years. J Prosthet Dent 2014; 112: 792–797.
- 140. Meyle J, Gersok G, Boedeker RH, Gonzales JR. Longterm analysis of osseointegrated implants in non-smoker patients with a previous history of periodontitis. J Clin Periodontol 2014; 41:504–512.
- 141. Pozzi A, Mura P. Clinical and radiologic experience with moderately rough oxidized titanium implants: up to 10 years of retrospective follow-up. Int J Oral Maxillofac Implants 2014; 29:152–161.
- 142. Anitua E, Pinas L, Begona L, Orive G. Long-term retrospective evaluation of short implants in the posterior areas: clinical results after 10-12 years. J Clin Periodontol 2014; 41:404–411.

- 143. Rasperini G, Siciliano VI, Cafiero C, Salvi GE, Blasi A, Aglietta M. Crestal bone changes at teeth and implants in periodontally healthy and periodontally compromised patients. A 10-year comparative case-series study. J Periodontol 2014; 85:e152–e159.
- 144. Mozzati M, Gallesio G, Del FM. Long-term (9-12 years) outcomes of titanium implants with an oxidized surface: a retrospective investigation on 209 implants. J Oral Implantol 2015; 41:437–443.
- 145. Zou D, Wu Y, Huang W, Zhang Z, Zhang Z. A 5- to 8-year retrospective study comparing the clinical results of implant-supported telescopic crown versus bar overdentures in patients with edentulous maxillae. Int J Oral Maxillofac Implants 2013; 28:1322–1330.
- 146. Donati M, La S, V, Di RR, Speroni S, Testi M, Berglundh T. Marginal bone preservation in single-tooth replacement: a 5-year prospective clinical multicenter study. Clin Implant Dent Relat Res 2015; 17:425–434.
- 147. Rocci A, Rocci M, Rocci C, et al. Immediate loading of Branemark system TiUnite and machined-surface implants in the posterior mandible, part II: a randomized open-ended 9-year follow-up clinical trial. Int J Oral Maxillofac Implants 2013; 28:891–895.
- 148. Dhima M, Balshi T, Wolfinger G, Petropoulos VC, Balshi S. A retrospective analysis of mandibular bone height changes associated with 81 screw-retained implant-supported prostheses with distal cantilevers: a long-term follow-up analysis. Int J Oral Maxillofac Implants 2013; 28:854–859.
- 149. Krennmair G, Seemann R, Weinlander M, Krennmair S, Piehslinger E. Clinical outcome and peri-implant findings of four-implant-supported distal cantilevered fixed mandibular prostheses: five-year results. Int J Oral Maxillofac Implants 2013; 28:831–840.
- 150. Akca K, Cavusoglu Y, Sagirkaya E, Cehreli MC. Early-loaded one-stage implants retaining mandibular overdentures by two different mechanisms: 5-year results. Int J Oral Maxillofac Implants 2013; 28:824–830.
- 151. Gelb D, McAllister B, Nummikoski P, Del FM. Clinical and radiographic evaluation of branemark implants with an anodized surface following seven-to-eight years of functional loading. Int J Dent 2013; 2013:583567.
- 152. Schwarz S, Bernhart G, Eiffler C, Hassel AJ, Lehmann F, Rammelsberg P. Early loading of implants with fixed dental prostheses in edentulous mandibles: 7.2-year clinical results from a prospective study. Clin Implant Dent Relat Res 2014; 16:904–912.
- 153. Wagenberg BD, Froum SJ, Eckert SE. Long-term bone stability assessment around 1,187 immediately placed implants with 1- to 22-year follow-up. Int J Oral Maxillofac Implants 2013; 28:605–612.
- 154. Sayardoust S, Grondahl K, Johansson E, Thomsen P, Slotte C. Implant survival and marginal bone loss at turned and oxidized implants in periodontitis-

- susceptible smokers and never-smokers: a retrospective, clinical, radiographic case-control study. J Periodontol 2013; 84:1775–1782.
- 155. Calvo-Guirado JL, Gomez-Moreno G, Delgado-Ruiz RA, Mate Sanchez de Val JE, Negri B, Ramirez Fernandez MP. Clinical and radiographic evaluation of osseotiteexpanded platform implants related to crestal bone loss: a 10-year study. Clin. Oral Implants Res 2014; 25: 352–358.
- 156. Lops D, Bressan E, Chiapasco M, Rossi A, Romeo E. Zirconia and titanium implant abutments for single-tooth implant prostheses after 5 years of function in posterior regions. Int J Oral Maxillofac Implants 2013; 28: 281–287.
- 157. Dam HG, Najm SA, Nurdin N, Bischof M, Finkelman M, Nedir R. A 5- to 6-year radiological evaluation of titanium plasma sprayed/sandblasted and acid-etched implants: results from private practice. Clin Oral Implants Res 2014; 25:e159–e165.
- 158. Buser D, Chappuis V, Bornstein MM, Wittneben JG, Frei M, Belser UC. Long-term stability of contour augmentation with early implant placement following single tooth extraction in the esthetic zone: a prospective, cross-sectional study in 41 patients with a 5- to 9-year follow-up. J Periodontol 2013; 84:1517–1527.
- 159. Lee KJ, Kim YG, Park JW, Lee JM, Suh JY. Influence of crown-to-implant ratio on periimplant marginal bone loss in the posterior region: a five-year retrospective study. J Periodontal Implant Sci 2012; 42:231–236.
- 160. Nickenig HJ, Wichmann M, Happe A, Zoller JE, Eitner S. A 5-year prospective radiographic evaluation of marginal bone levels adjacent to parallel-screw cylinder machined-neck implants and rough-surfaced microthreaded implants using digitized panoramic radiographs. J Craniomaxillofac Surg 2013; 41:564–568.
- 161. Kokovic V, Jung R, Feloutzis A, Todorovic VS, Jurisic M, Hammerle CH. Immediate vs. early loading of SLA implants in the posterior mandible: 5-year results of randomized controlled clinical trial. Clin Oral Implants Res 2014; 25:e114–e119.
- 162. Mertens C, Meyer-Baumer A, Kappel H, Hoffmann J, Steveling HG. Use of 8-mm and 9-mm implants in atrophic alveolar ridges: 10-year results. Int J Oral Maxillofac Implants 2012; 27:1501–1508.
- 163. Renvert S, Lindahl C, Rutger PG. The incidence of periimplantitis for two different implant systems over a period of thirteen years. J Clin Periodontol 2012; 39: 1191–1197.
- 164. Mordenfeld A, Albrektsson T, Hallman M. A 10-year clinical and radiographic study of implants placed after maxillary sinus floor augmentation with an 80:20 mixture of deproteinized bovine bone and autogenous bone. Clin Implant. Dent Relat Res 2014; 16:435–446.

- 165. Mir-Mari J, Mir-Orfila P, Valmaseda-Castellon E, Gay-Escoda C. Long-term marginal bone loss in 217 machined-surface implants placed in 68 patients with 5 to 9 years of follow-up: a retrospective study. Int J Oral Maxillofac Implants 2012; 27:1163–1169.
- 166. Horwitz J, Machtei EE. Immediate and delayed restoration of dental implants in patients with a history of periodontitis: a prospective evaluation up to 5 years. Int J Oral Maxillofac Implants 2012; 27:1137–1143.
- 167. Deporter D, Pharoah M, Yeh S, Todescan R, Atenafu EG. Performance of titanium alloy sintered porous-surfaced (SPS) implants supporting mandibular overdentures during a 20-year prospective study. Clin Oral Implants Res 2014; 25:e189–e195.
- 168. Dierens M, de BE, Vandeweghe S, Kisch J, de Bruyn H, Cosyn J. Alterations in soft tissue levels and aesthetics over a 16-22 year period following single implant treatment in periodontally-healthy patients: a retrospective case series. J Clin Periodontol 2013; 40:311–318.
- 169. Buser D, Janner SF, Wittneben JG, Bragger U, Ramseier CA, Salvi GE. 10-year survival and success rates of 511 titanium implants with a sandblasted and acid-etched surface: a retrospective study in 303 partially edentulous patients. Clin Implant Dent Relat Res 2012; 14:839–851.
- 170. Frisch E, Ziebolz D, Rinke S. Long-term results of implantsupported over-dentures retained by double crowns: a practice-based retrospective study after minimally 10 years follow-up. Clin Oral Implants Res 2013; 24:1281–1287.
- 171. Camargos G,V, do Prado CJ, das Neves FD, Sartori IA. Clinical outcomes of single dental implants with external connections: results after 2 to 13 years. Int J Oral Maxillofac Implants 2012; 27:935–944.
- 172. Lops D, Bressan E, Pisoni G, Cea N, Corazza B, Romeo E. Short implants in partially edentuolous maxillae and mandibles: a 10 to 20 years retrospective evaluation. Int J Dent 2012; 2012:351793.
- 173. Ormianer Z, Piek D, Livne S, et al. Retrospective clinical evaluation of tapered implants: 10-year follow-up of delayed and immediate placement of maxillary implants. Implant Dent 2012; 21:350–356.
- 174. Lang LA, Turkyilmaz I, Edgin WA, Verrett R, Garcia LT. Immediate restoration of single tapered implants with non-occluding provisional crowns: a 5-year clinical prospective study. Clin Implant Dent Relat Res 2014; 16:248–258.
- 175. Ravald N, Dahlgren S, Teiwik A, Grondahl K. Long-term evaluation of Astra Tech and Branemark implants in patients treated with full-arch bridges. Results after 12-15 years. Clin Oral Implants Res 2013; 24:1144–1151.
- 176. Deporter DA, Kermalli J, Todescan R, Atenafu E. Performance of sintered, porous-surfaced, press-fit implants after 10 years of function in the partially edentulous posterior mandible. Int J Periodontics Restorative Dent 2012; 32:563–570.

- 177. Jungner M, Lundqvist P, Lundgren S. A retrospective comparison of oxidized and turned implants with respect to implant survival, marginal bone level and peri-implant soft tissue conditions after at least 5 years in function. Clin Implant Dent Relat Res 2014; 16:230–237.
- 178. Francetti L, Azzola F, Corbella S, Taschieri S, Del FM. Evaluation of clinical outcomes and bone loss around titanium implants with oxidized surface: six-year follow-up results from a prospective case series study. Clin Implant Dent Relat Res 2014; 16:81–88.
- 179. Ostman PO, Hellman M, Sennerby L. Ten years later.
   Results from a prospective single-centre clinical study on
   121 oxidized (TiUnite) Branemark implants in 46
   patients. Clin Implant Dent Relat Res 2012; 14:852–860.
- 180. Arnhart C, Dvorak G, Trefil C, Huber C, Watzek G, Zechner W. Impact of implant surface topography: a clinical study with a mean functional loading time of 85 months. Clin Oral Implants Res 2013; 24:1049–1054.
- 181. Lai HC, Si MS, Zhuang LF, Shen H, Liu YL, Wismeijer D. Long-term outcomes of short dental implants supporting single crowns in posterior region: a clinical retrospective study of 5-10 years. Clin Oral Implants Res 2013; 24:230–237.
- 182. Hayacibara RM, Goncalves CS, Garcez-Filho J, Magro-Filho O, Esper H, Hayacibara MF. The success rate of immediate implant placement of mandibular molars: a clinical and radiographic retrospective evaluation between 2 and 8 years. Clin Oral Implants Res 2013; 24:806–811.
- 183. Degidi M, Nardi D, Piattelli A. 10-year follow-up of immediately loaded implants with TiUnite porous anodized surface. Clin Implant Dent Relat Res 2012; 14:828–838.
- 184. Levine RA, Sendi P, Bornstein MM. Immediate restoration of nonsubmerged titanium implants with a sandblasted and acid-etched surface: five-year results of a prospective case series study using clinical and radiographic data. Int J Periodontics Restorative Dent 2012; 32:39–47.
- 185. Rodrigo D, Martin C, Sanz M. Biological complications and peri-implant clinical and radiographic changes at immediately placed dental implants. A prospective 5year cohort study. Clin Oral Implants Res 2012; 23: 1224–1231.
- 186. Heschl A, Payer M, Platzer S, Wegscheider W, Pertl C, Lorenzoni M. Immediate rehabilitation of the edentulous mandible with screw type implants: results after up to 10 years of clinical function. Clin Oral Implants Res 2012; 23:1217–1223.
- 187. Lethaus B, Kalber J, Petrin G, Brandstatter A, Weingart D. Early loading of sandblasted and acid-etched titanium implants in the edentulous mandible: a prospective 5-year study. Int J Oral Maxillofac Implants 2011; 26:887–892.
- 188. Heschl A, Payer M, Clar V, Stopper M, Wegscheider W, Lorenzoni M. Overdentures in the edentulous mandible supported by implants and retained by a Dolder bar: a

- 5-year prospective study. Clin Implant Dent Relat Res 2013; 15:589–599.
- 189. Browaeys H, Defrancq J, Dierens MC, et al. A retrospective analysis of early and immediately loaded osseotite implants in cross-arch rehabilitations in edentulous maxillas and mandibles up to 7 years. Clin Implant Dent Relat Res 2013; 15:380–389.
- 190. Turkyilmaz I, Tozum TF, Fuhrmann DM, Tumer C. Seven-year follow-up results of TiUnite implants supporting mandibular overdentures: early versus delayed loading. Clin Implant Dent Relat Res 2012; 14 Suppl 1:e83–e90.
- 191. Glauser R. Implants with an oxidized surface placed predominately in soft bone quality and subjected to immediate occlusal loading: results from a 7-year clinical follow-up. Clin Implant. Dent Relat Res 2013; 15:322–331.
- 192. Soardi E, Cosci F, Checchi V, Pellegrino G, Bozzoli P, Felice P. Radiographic analysis of a transalveolar sinus-lift technique: a multipractice retrospective study with a mean follow-up of 5 years. J Periodontol 2013; 84:1039–1047.
- 193. Calvo-Guirado JL, Gomez-Moreno G, Lopez-Mari L, Guardia J, Negri B, Martinez-Gonzalez JM. Crestal bone loss evaluation in osseotite expanded platform implants: a 5-year study. Clin Oral Implants Res 2011; 22:1409–1414.
- 194. Kowar J, Eriksson A, Jemt T. Fixed implant-supported prostheses in elderly patients: a 5-year retrospective comparison between partially and completely edentulous patients aged 80 years or older at implant surgery. Clin Implant Dent Relat Res 2013; 15:37–46.
- 195. Geckili O, Mumcu E, Bilhan H. Radiographic evaluation of narrow diameter implants after 5 years of clinical function: a retrospective study. J Oral Implantol 2011 (Epub ahead of print).
- 196. Cochran DL, Jackson JM, Jones AA, et al. A 5-year prospective multicenter clinical trial of non-submerged dental implants with a titanium plasma-sprayed surface in 200 patients. J Periodontol 2011; 82:990–999.
- 197. Mertens C, Steveling HG. Implant-supported fixed prostheses in the edentulous maxilla: 8-year prospective results. Clin Oral Implants Res 2011; 22:464–472.
- 198. Roccuzzo M, Bonino F, Aglietta M, Dalmasso P. Tenyear results of a three arms prospective cohort study on implants in periodontally compromised patients. Part 2: clinical results. Clin Oral Implants Res 2012; 23:389–395.
- Zitzmann NU, Berglundh T. Definition and prevalence of peri-implant diseases. J Clin Periodontol 2008; 35(8 Suppl):286–291.
- 200. Hammerle CH, van SD. The first EAO consensus conference 16-19 February 2006, Pfaffikon, Switzerland. Clin Oral Implants Res 2006; 17 Suppl 2:1.

- 201. De Bruyn H, Vandeweghe S, Ruyffelaert C, Cosyn J, Sennerby L. Radiographic evaluation of modern oral implants with emphasis on crestal bone level and relevance to peri-implant health. Periodontol 2000 2013; 62:256–270.
- 202. Canullo L, Iannello G, Penarocha M, Garcia B. Impact of implant diameter on bone level changes around platform switched implants: preliminary results of 18 months follow-up a prospective randomized match-paired controlled trial. Clin Oral Implants Res 2012; 23:1142–1146.
- 203. Broggini N, McManus LM, Hermann JS, et al. Periimplant inflammation defined by the implant-abutment interface. J Dent Res 2006; 85:473–478.
- 204. Broggini N, McManus LM, Hermann JS, et al. Persistent acute inflammation at the implant-abutment interface. J Dent Res 2003; 82:232–237.
- 205. Hermann JS, Schoolfield JD, Nummikoski PV, Buser D, Schenk RK, Cochran DL. Crestal bone changes around titanium implants: a methodologic study comparing linear radiographic with histometric measurements. Int J Oral Maxillofac Implants 2001; 16:475–485.
- 206. Albouy JP, Abrahamsson I, Persson LG, Berglundh T. Spontaneous progression of ligatured induced periimplantitis at implants with different surface characteristics. An experimental study in dogs II: histological observations. Clin Oral Implants Res 2009; 20:366–371.
- 207. Albouy JP, Abrahamsson I, Persson LG, Berglundh T. Spontaneous progression of peri-implantitis at different types of implants. An experimental study in dogs. I: clinical and radiographic observations. Clin Oral Implants Res 2008; 19:997–1002.
- 208. Berglundh T, Gotfredsen K, Zitzmann NU, Lang NP, Lindhe J. Spontaneous progression of ligature induced peri-implantitis at implants with different surface roughness: an experimental study in dogs. Clin Oral Implants Res 2007; 18:655–661.
- 209. Vandeweghe S, Cosyn J, Thevissen E, Van den Berghe L, De Bruyn H. A 1-year prospective study on Co-Axis implants immediately loaded with a full ceramic crown. Clin Implant Dent Relat Res 2012; 14 Suppl 1:e126–e138.
- 210. Albrektsson T, Buser D, Chen ST, et al. Statements from the Estepona consensus meeting on peri-implantitis, February 2-4, 2012. Clin Implant Dent Relat Res 2012; 14:781–782.
- 211. Klinge B, Meyle J. Peri-implant tissue destruction. The third EAO consensus conference 2012. Clin Oral Implants Res 2012; 23 Suppl 6:108–110.
- 212. Dierens M, Vandeweghe S, Kisch J, Nilner K, De Bruyn H. Long-term follow-up of turned single implants placed in periodontally healthy patients after 16-22 years: radiographic and peri-implant outcome. Clin Oral Implants Res 2012; 23:197–204.